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Supervisor: Prof. Dr. Mehmet Öztürk 
August 2010, 83 Pages 
 
 
 
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers 
worldwide. The epigenetic modifications, which are involved in virtually all cellular 
processes are also involved in the carcinogenic process, and this is a growing new 
field of investigation. HCC has also been associated with several epigenetic 
aberrations which include the ones in histone modifications, histone 
methyltransferase enzymes, and the epigenetic machinery. The transition from 
cirrhosis to HCC is related to senescence bypass, and the distinctions between 
senescence and immortality in HCC cell lines. Global levels of H3K4me3, 
H3K9me3, H3K27me3, H3K36me3, H3R2me2, H3R17me2 and H4K20me3 histone 
marks were evaluated in well-differentiated and poorly differentiated HCC cell lines 
in the presence and absence of TGF-β induced senescence. No prominent changes in 
the levels of these histone modifications were indentified in response to TGF-β 
induced senescence. However, H4K20me3 levels appeared to correlate with the 
differentiation status of the cell lines, where a loss of methylation was observed in 
poorly differentiated cell lines. In order to address the mechanism of this loss, 
H4K20 specific methyltransferases were analyzed in terms of their transcript levels, 
and only the expression pattern of monomethyl transferase Set8 was found to 
correlate with the H4K20me3 methylation patterns. A potential role played by Set8 
in HCC development was investigated via overexpression and knockdown studies. 
But no significant role could be attributed to this enzyme in this study. 
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ÖZET 
 
KARACİĞER KANSERİNDE HİSTON METİLASYONU  
VE METİLTRANSFERAZ ENZİMİ SET8 
 
Eylül Harputlugil 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 2010, 83 Sayfa 
 
 
Karaciğer kanseri (Hepatoselüler Karsinom, HSK), dünya genelindeki en yaygın ve 
ölümcül kanser türlerinden biridir. Hücredeki hemen hemen her olayda rol oynayan 
epigenetik değişimler, kanser oluşumunda da etkilidir, ve bu araştırma alanı giderek 
genişlemektedir. HSK da, histon modifikasyonları, histon metiltransferaz enzimleri 
ve epigenetik mekanizmadaki bozuklukları da içeren çeşitli epigenetik bozukluklar 
ile özdeşleştirilmiştir. Sirozdan karaciğer kanserine geçiş, hücre yaşlanması 
(senesans) durumunun aşılması ile ilintilidir, ve bu durum hücre hattı modellerinde 
görülen ölümsüzlük ve hücre yaşlanması durumları arasındaki farklar ile de 
ilişkilendirilmiştir. H3K4me3, H3K9me3, H3K27me3, H3K36me3, H3R2me2, 
H3R17me2 ve H4K20me3 histon işaretlerinin global seviyeleri, iyi diferansiye ve 
kötü diferansiye hücre hatlarında, ölümsüzlük ve TGF-β tarafından indüklenen hücre 
yaşlanması durumlarında incelenmiştir. TGF-β’nın indüklediği hücre yaşlanması 
durumunda, sözü edilen histon işaretlerinde göze çarpan bir değişiklik görülmemiştir. 
Buna karşın, H4K20me3 seviyelerinin hücrelerin farklılaşma durumu ile ilişkisi 
olduğu, ve kötü diferansiye hücre hatlarına özgü bir kayba uğradıkları saptanmıştır.   
Söz konusu kaybın mekanizmasını araştırmak amacıyla, H4K20 rezidüsüne özgü 
metiltransferazların tüm izoformlarının ifade seviyeleri hücre hatlarında incelenmiş, 
ve yalnızca Set8 enziminin ifade düzeninin H4K20 trimetilasyon düzeni ile örtüştüğü 
tespit edilmiştir. Set8 enziminin hepatoselüler karsinom oluşumunda oynadığı olası 
bir rolü araştırmak amacıyla enzimin ifadesini arttıran ve susturan çalışmalar 
yapılmıştır. Ancak sözü edilen çalışmalar sonucunda Set8 enzimine bu konuda 
anlamlı bir görev atfedilememiştir. 
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CHAPTER 1. INTRODUCTION 
1.1. HEPATOCELLULAR CARCINOMA 
More than 80 % of liver cancers arise from hepatocytes or hepatocyte progenitors, 
which are the parenchymal cells of the liver (American Cancer Society, Facts and 
Figures 2010). These cancers are accordingly named as hepatocellular carcinoma 
(HCC). HCC is highly frequent, being the fifth most frequent cancer worldwide, and 
has increasing rates of incidence and mortality in the West since 1980s (Bruix, J et 
al, 2004). HCC is also an important cause of cancer related death, with a 5 year 
relative survival rate of 14 % (American Cancer Society, 2010). 
 
1.1.1 Aetiologies of hepatocellular carcinoma 
There are several aetiological factors that have been associated with 
hepatocarcinogenesis, which include: chronic alcohol abuse, Aflatoxin B1 exposure; 
which might occur by the consumption of contaminated food, chronic HBV or HCV 
infections, non-alcoholic fatty liver disease; which is also associated with obesity, 
long-term oral contraceptive use in women,  diabetes, and finally certain metabolic 
disorders such as hereditary haemochromatosis (Badvie S, et al, 2000; Farazi PA, et 
al, 2006). The most prevalent risk factors of HCC are variable due to regionality, for 
example chronic HBV and HCV infections are the major risk factors worldwide, 
whereas these cases constitute less than half in the US. In most western countries, the 
major risk factors of hepatocarcinogenesis are alcoholic cirrhosis and obesity related 
non-alcoholic fatty liver disease (American Cancer Society, 2010).  
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1.1.2 Pathogenesis of hepatocellular carcinoma 
Molecular mechanisms leading to the development of HCC are quite variable, 
representing the variability of HCC aetiology, which results in high genetic and 
phenotypic heterogeneity of these tumors. HCC development occurs in chronically 
injured livers, in a multi-step process (Feo F, et al, 2009). Liver injury might result 
from one or more of the major HCC risk factors, such as chronic Hepatitis B Virus 
(HBV) or Hepatitis C Virus (HCV) infections, alcohol-related cirrhosis, Aflatoxin 
B1 exposure, or genetic disorders. The initial liver injury manifests itself as necrosis, 
which is followed by continuous cycles of proliferation and damage. On the one 
hand, these continuous cycles of proliferation and necrosis cause telomere 
shortening, which eventually result in hepatocyte proliferative arrest. On the other 
hand, liver injury provokes activation of stellate cells, which play role in the 
synthesis and deposition collagen. Both of these contribute to the formation of 
abnormal liver nodules, together with fibrous scar tissue, a state which is called 
cirrhosis (Feo F, et al, 2009; Farazi PA, et al, 2006). Formation of hyperplastic 
nodules is the next step in the pathogenesis of HCC, which are still considered as 
pre-malignant lesions. Together with the accumulation of genetic damage, leading to 
moderate genomic instability, these pre-malignant lesions progress into dysplastic 
nodules which have the ability of autonomous growth. Dysplastic nodules are 
composed of cells with altered characteristics such as increased nuclear to 
cytoplasmic ratio, and they tend to form mild trabecular disarrays (Feo F, et al, 
2009). 
 
Where telomere shortening is associated with chronic liver disease and cirrhosis as 
mentioned, telomerase reactivation is an important characteristic of HCC, together 
with notable genomic instability and either mutation or loss of p53 tumor suppressor. 
Although, the specific stages at which these changes occur is not clear, aided with 
these molecular changes, dysplastic nodules evolve progressively into different 
stages of hepatocellular carcinoma (Farazi PA, et al, 2006). HCC can be classified 
into four different stages, namely: well differentiated, moderately differentiated, 
poorly differentiated and undifferentiated. Generally, HCC arises as a well 
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differentiated cancer, which then dedifferentiates into the other stages through a 
stepwise process (Kojiro M, 2005; Yuzugullu H, et al, 2009). 
 
1.1.3 Cellular senescence  
The term senescence means ―becoming old‖ in the general sense, and it is associated 
with certain morphological and gene-expression related features. The inability of cell 
strains to grow indefinitely in culture was first described by Hayflick, who used the 
term ―cellular senescence‖ (Weinberg RA, The Biology of Cancer). Replicative 
senescence is characterized by irreversible cell cycle arrest due to telomere 
shortening, and in addition to that,  there are also other immature senescence types 
which occur due to stress and damage (Ozturk M, et al, 2009). These stress and 
damage conditions that are known to induce senescence include oncogenic stress, 
which results in oncogene induced senescence (Bartkova J, et al, 2006; Di Micco R, 
et al, 2006; Mallette FA, et al, 2007) and oxidative stress, which results in Reactive 
Oxygen Species (ROS) induced senescence. Additionally, exposure to certain 
signaling molecules have also been shown to induce senescence, such as TGF-β or β-
interferon in various cell types (Senturk S, et al, 2010; Moisseva O, et al, 2006). 
 
Senescent cells exhibit certain characteristic features such as senescence-associated 
β-galactosidase (SABG) activity at pH 6.0, altered morphology resulting in diverse 
morphotypes and usually bigger cells, formation of senescence-associated DNA 
damage foci and  senescence associated heterochromatin foci, chromosomal 
aberrations and polyploidy, and alterations in the expression of several genes. 
Although they all involve different mechanisms, all senescence pathways converge 
on the DNA damage response (DDR) (Ozturk M, et al, 2009). In telomere dependent 
senescence pathway, unprotected telomere ends resulting from telomere shortening 
are sensed as DNA damage. In oncogene induced senescence pathway, hyper-
replication of cells which is promoted by the oncogenes result in accumulation of 
DNA replication errors. And finally in ROS induced senescence pathway, reactive 
oxygen species directly cause DNA damage themselves. Therefore, persistent DNA 
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damage and DDR is of pivotal importance in all senescence pathways. The DNA 
damage response involves activation of signaling cascades that involve the actions of 
ATM/ATR and CHK1/CHK2, and converge on p53 protein, which acts through 
p21
cip1
 cyclin dependent kinase inhibitor (CDKI) activation. Alternative pathways 
converge on p16
INK4a
 and p15
INK4b
 CDKIs. Both CDKI pathways lead to the 
activation of retinoblastoma  protein (pRb), which then plays role in the arrest of cell 
cycle, and thus senescence phenotype occurs (Ozturk M, et al, 2009; Senturk S, et al, 
2010).  
 
1.1.4 Senescence and hepatocellular carcinoma 
Like most of the human somatic cells, hepatocytes normally do not have telomerase 
activity and they do not proliferate rapidly. The continuous rounds of cell division 
and damage cycles which pave the way to chronic liver injury and cirrhosis also play 
role in the shortening of telomeres. Therefore, cellular senescence which is 
associated with hepatocyte telomere shortening is a general characteristic of liver 
cirrhosis. This was illustrated by SABG staining in normal and cirrhotic livers, which 
revealed 84 % senescent cells in cirrhosis as opposed to only 10 % in normal liver 
(Wiemann SU, et al, 2002). However, in order to undergo malignant transformation, 
cells have to find a way to regain their ability to proliferate, and to maintain their 
telomeres while doing so. In that context, cellular senescence acts as a barrier in front 
of malignant transformation of hepatocytes to hepatocellular carcinoma. This was 
also supported by a study which showed 60 % SABG staining in HCC samples 
(Paradis V, et al, 2001). 
 
Numerous genetic and epigenetic aberrations have been associated with 
hepatocarcinogenesis, that effect important actors of senescence induction, therefore 
help the cells to overcome the senescence barrier. These aberrations include 
inactivating mutations of p53, which is frequently observed in HCC (Soussi, T, 
2007). Despite the lack of frequent mutations, CDK inhibitor p16
INK4a
 is 
epigenetically silenced in half of the HCCs through promoter methylation (Ozturk 
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M, et al, 2009). According to a study which analyzed molecular aberrations in HCC 
samples from different aetiological backgrounds, 83 % of the analyzed HCC samples 
displayed alterations in the pRb pathway components, 31 % displayed alterations in 
p53 pathway components, and  30 % displayed both (Edamoto Y, et al, 2003; Ozturk 
M, et al, 2009).  
 
Taken as a whole, the aberrations explained above are likely to play an important 
role in overcoming the senescence barrier, together with the possible involvement of 
telomerase reactivation. Molecular understanding of the mechanisms that drive 
senescence, senescence bypass, and senescence induction in cancer cells is very 
important since senescence induction is considered as a potential new area of anti-
cancer therapy. A recent study by our group described the molecular mechanisms of 
TGF-β induced senescence in HCC cell lines, and showed that the specific 
senescence program was dependent on p21
Cip1
 and p15
INK4b
, but independent from 
p53 and p16
INK4a
 (Senturk S, et al, 2010). 
 
1.2. EPIGENETIC CHANGES AND HEPATOCELLULAR CARCINOMA 
Although originally defined in a different context, the term epigenetics is currently 
used to mean heritable changes in the DNA or its associated proteins, which is 
independent from the DNA sequence information (Feinberg AP, et al, 2010). 
Mechanisms of epigenetic control include DNA methylation, covalent histone 
modifications and involvement of histone variants in the chromatin structure, which 
actively take role in an interplay. These factors, together with chromatin remodeling 
complexes and non-coding RNAs, play role in the determination of the chromatin 
structure. They interact in order to attain nuclear compartmentalization, as well as to 
establish heterochromatic and euchromatic regions of the chromatin. Epigenetic 
control has been shown to be involved in virtually all biological processes, which 
vary from embryogenesis, and cellular differentiation to learning, memory and aging 
(Delcuve GP, et al, 2009). As can easily be seen from this fact, errors which occur 
during the establishment or maintenance of the epigenetic codes play role in the 
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development of various diseases including cancer. Since epigenetic codes are more 
versatile in comparison to the genetic code, it is important to understand the 
mechanisms involved in the formation and upholding of these codes, in order to be 
able to reverse such errors, which makes epigenetic therapy an attractive new field. 
 
1.2.1 DNA methylation 
In the human genome, most of the CpG dinucleotides are methylated at the C
5
 
position of cytosine bases, which is commonly referred to as DNA methylation. 
About 50 % of the CpG dinucleotides are concentrated in promoter regions, as well 
as 5’ untranslated  regions of genes, and the remaining 50 % is located in the 
intragenic regions or the gene bodies (Delcuve GP, et al, 2009). These regions with 
concentrated CpG dinucleotides are referred to as CpG islands. DNA methylation 
which occurs in the CpG islands at gene promoters has generally been associated 
with gene silencing, in contrast to the DNA methylation in gene bodies, which might 
be involved in transcriptional activation (Hellman A, et al, 2007). Additionally, CpG 
island methylation is also observed in repetitive DNA sequences and transposable 
elements, and it might play a role in preventing translocations (Esteller, M, 2007).  
 
Cancer development involves two type of aberrant DNA methylation processes, both 
hypermethylation and hypomethylation. The better established mode of DNA 
methylation alteration observed in various cancers is DNA hypermethylation found 
in the promoter regions in several tumor suppressors, which results in silencing of 
those genes. This process is responsible, at least in part, for escaping from apoptosis, 
loss of cell adhesion and angiogenesis, which are common features of tumors 
(Herceg Z, 2007). Although the direct mechanism of action has not been well 
established, global hypomethylation is observed in almost all types of cancers. It is 
hypothesized that global hypomethylation might act through several mechanisms 
which include: loss of imprinting, inappropriate cell type expression, genome 
vulnerability or the activation of endoparasitic sequences (Esteller, M, 2007). 
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Studies have revealed that promoter hypermethylation of tumor suppressor genes is 
an early event in hepatocellular carcinogenesis, given that it has been observed in 
non-cancerous liver tissues. The genes that have been shown to be silenced via 
promoter hypermethylation in HCC include: p16
INK4a
, DLC1, E-Cadherin, PTEN, 
and many others (Wong CM, et al, 2007). 
 
1.2.2 Histone variants and genomic imprinting 
Genomic imprinting is an epigenetically regulated phenomenon, which is observed in 
a limited set of genes, where genes exhibit expression differences depending on 
whether they are paternally or maternally inherited (Jelinic P, et al, 2007). Genes 
which are subject to genomic imprinting appear in clusters, and the expression from 
those genes is coordinately regulated by imprinting control centers. DNA 
methylation is observed in only one allele in imprinting control centers, depending 
on which allele is to be expressed, additionally covalent histone modifications and 
recruitment of non conventional histone variants are involved in the process (Delaval 
K, et al, 2004). This heterochromatin structure is established in embryonic stages, 
and maintained in the adult organism, misregulation of which might result in loss of 
imprinting: one of the accepted hallmarks of cancer (Jelinic P, et al, 2007).  
 
Genes which are subject to genomic imprinting usually have functions in embryonic 
development, placenta formation and adult metabolism. Some of the best studied 
examples of these genes include: Igf2, H19, Igf2R and Kvlqt. H19 imprinting control 
center is located at chromosome 11p15.5, and is responsible for the expression from 
Igf2 and H19 genes, which have opposite monoallelic expression (Matouk IJ, et al, 
2007).  Igf2 gene codes for a fetal growth factor, and H19 codes for a non translated 
RNA message, and anomalies of both have been associated with the pathogenesis of 
HCC (Boyault S, et al, 2007). In a study which compared normal liver and HCC 
samples, it was shown that around 40 % of the studied HCC samples displayed 
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abnormal genomic imprinting in at least one of these two genes, which was 
manifested as biallelic expression due to loss of imprinting (Wu J, et al, 2008). 
 
Histone variants, which are low expressed, non-allelic forms of the conventional 
histones, serve in providing specific structural and functional characteristics to the 
nucleosome (Talbert PB, et al, 2010). These characteristics include gene expression 
control, genomic imprinting, X-chromosome inactivation and DNA repair. For 
example,  macro-H2A1 histone variant was shown to be enriched in the inactive X-
chromosome, and imprinted loci such as the Igf2/H19 imprinting control center, 
whereas H2ABbd histone variant was implicated in promoting gene expression 
(Mietton F, et al, 2009; Sha K, 2008). More interestingly, histone variants have also 
been implicated in processes such as senescence, specifically macro-H2A histone 
variant nucleosomes were found to be enriched in senescence-associated 
heterochromatin foci, although it is not clear that the role played by this histone 
variant is causative (Zhang R, et al, 2005; Bushbeck M, et al, 2010). Additionally, 
low levels of macroH2A histone variant were found to be in correlation with high 
proliferation and bad prognosis in lung cancer (Bushbeck M, et al, 2010). Taken as a 
whole, these cases exemplify the potential importance of histone variants in cancer. 
 
1.2.3 Covalent histone modifications 
DNA is wrapped around octameric protein structures which consist of the four so 
called core histones: H2A, H2B, H3 and H4. The histone octamer has a globular 
domain, which functions in packaging the DNA, as well as free ―tail‖ structures 
which protrude out from the N-terminal ends of histone proteins. These tail regions 
of histones are particularly of interest, due to the importance of diverse sets of 
covalent modifications that they can be subjected to. At least eight different types of 
such modifications have been described in no less than 60 different modification 
sites to date, which include: acetylation of lysines, methylation of lysine and 
arginines, phosphorylation of serine and threonines, ubiquitylation of lysines, 
sumoylation of lysines, deimination of arginines, ADP ribosylation of glutamic acids, 
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and finally proline isomerization, which are all associated with certain biological 
processes (Kouzarides T, 2007; Wang GG, et al, 2007). Among all these 
modifications, the best studied ones are acetylations, methylations and 
phosphorylations.  
 
These modifications were shown to get  involved in biological processes by two 
mechanisms. The first mechanism is interfering with nucleosome contacts, which 
results in disentanglement of the chromatin structure. The second and better 
characterized mechanism involves interacting with and recruiting certain proteins to 
the nucleosome, or oppositely, detaching certain proteins from the nucleosome. 
Hence, histone modifications are key players of the determination of the accessibility 
of the chromatin, and their involvement in cancer pathogenesis is a growing new 
field (Kouzarides T, 2007; Wang GG, et al, 2007). 
 
1.2.3.1 Histone acetylations, acetyltransferase and deacetylase enzymes 
Several lysine residues on histone H3 and H4 tails are subject to acetylation by 
numerous histone acetyltransferase enzymes (HATs), some of which are: HAT1, 
CBP/P300, PCAF/GCN5, TIP60 and HB01 (Kouzarides T, 2007). HATs are poorly 
specific for their histone and non-histone substrates in the sense that they are capable 
of acetylating multiple residues on histones, and they also have non-histone 
substrates including E2F, p53 and pRb (Yang XJ, et al, 2004; Wang GG, et al, 2007). 
 
Since the acetylation status of histone tails is of crucial importance for the formation 
of chromatin architecture, as well as regulation of gene expression, it is easy to 
deduce that misregulation of HAT activity might be involved in pathological 
conditions. Accordingly, disruption and misregulation of several HATs have been 
associated with different cancers. Mechanistically, decreased levels of histone 
acetylation is thought to give rise to a more compact chromatin structure, and hence 
transcription factors and RNA polymerases cannot access the chromatin. 
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Importantly, loss of acetylation in histone 4 lysine 16 has been detected in repetitive 
DNA sequences in many primary tumors (Wang GG, et al, 2007). However, 
interestingly, both aberrant activation and inactivation of HDAC enzymes were 
observed in malignancies (Ellis L, et al, 2009). 
 
Histone acetylation is dynamic, and can be reversed by histone deacetylase enzymes 
(HDACs) which have opposing roles with HATs. HDACs are likely to function in 
transcriptional repression since they decrease histone acetylation levels. There are 
more than 10 HDACs currently identified, and they are similarly misregulated in 
various cancer types (Ellis L, et al, 2009). Again similarly as the HATs, HDACs are 
also poorly specific for their histone and non-histone substrates. Instead, the general 
paradigm is that they gain specificity by interacting with proteins which carry 
HDACs to their specific localizations. In the recent years HDAC inhibitors have 
emerged as a new class of anticancer drugs showing potential. Although the 
mechanism of action of this new class of drugs in still incompletely described, it is 
known that they display a variety of cellular effects. Some of these effects are 
induction of apoptosis, differentiation and growth arrest (Wang GG, et al, 2007).  
 
1.2.3.2 Histone methylations, methyltransferase and demethylase enzymes 
Numerous lysine and arginine residues in the N-terminal tails of histone H3 and 
histone H4 are subject to methylation by histone methyltransferase enzymes (HMTs). 
All of these residues can have mono, di or trimethyl groups attached to them. 
Although it was long thought that histone lysine methylation is irreversible, it is now 
well established that lysine methylation is also dynamically regulated through several 
demethylase enzymes (Trojer P, et al, 2006; Kouzarides T, 2007). A summary of 
HMT and demethylase enzymes acting on several residues is shown in Table 1.1. 
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Residues 
Modified 
Lysine 
Methyltransferases 
Lysine Demethylases 
Arginine 
Methlytransferases 
H3K9 
SUV39H1 
SUV39H2 
G9a 
ESET/SETDB1 
EuHMTase/GLP 
CLL8 
RIZ1 
 
JHDM2a 
JHDM2b 
JMJD2A/JHDM3A 
JMJD2B 
JMJD2C/GASC1 
JMJD2D 
 
H3K4 
MLL1 
MLL2 
MLL3 
MLL4 
MLL5 
SET1A 
SET1B 
SET1 
LSD1/BHC110  
H3K36 
SET2  
NSD1 
SYMD2 
JHDM1a 
JHDM1b 
JMJD2A/JHDM3A 
JMJD2C/GASC1 
 
H3K79 DOT1   
H4K20 
SET8 
SUV420H1 
SUV420H2 
  
H3K27 EZH2   
H3 (R2, R17, 26)   CARM1 
H4R3   PRMT4 
H3R8, H4R3   PRMT5 
 
Table 1.1: Summary of histone methyltransferases and histone demethylases. (Adapted from 
Kouzarides T, 2007) 
 
Involvement of histone methylation processes in various biological phenomena is 
diverse. Unlike the relative uniformity of the association between histone acetylation 
and open chromatin conformation, the methylated residues and the degree of 
methylation result in dramatically different outcomes (Trojer P, et al, 2006). 
Generally, histone 3 lysine 4 (H3K4), histone 3 lysine 36 (H3K36), and histone 3 
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lysine 79 (H3K79) methylations have been associated with transcriptional activation 
and a more relaxed and open chromatin structure in contrast to histone 3 lysine 9 
(H3K9), histone 3 lysine 27 (H3K27), and histone 4 lysine 20 (H4K20) methylations, 
which were found to be enriched in heterochromatic regions, and were linked with 
transcriptional repression, as well as a condensed chromatin state (Trojer P, et al, 
2006; Wang GG, et al, 2007). Nevertheless, exceptions to this generalization do 
exist, and have been described by newly emerged next generation sequencing 
technologies which were coupled with chromatin immunoprecipitation (ChIP) 
technique. According to the analysis of various histone modifications on the whole 
genome scale, it was revealed that H3K27, H3K9, and H4K20 monomethylated 
forms were associated with gene activation. The trimethylated forms of H3K27 and 
H3K9 were confirmed to be involved in gene repression, which is in accordance with 
the conventional understanding. Still, trimethylated H3K79 was also implicated in 
gene repression (Ellis L, et al, 2009).  
 
There are several lines of evidence showing  the involvement of various histone 
methylations, and the enzymes functioning in histone methylation processes, in 
carcinogenesis, including hepatocarcinogenesis (Ellis L, et al, 2009). Some of the 
examples include tumor cell selective loss of global H4K20me3 levels, which is very 
well established (Fraga MF, et al, 2005). This was observed in numerous cancer 
models, including a rodent model of HCC, which was induced by methyl-deficient 
diet (Pogribny IP, et al, 2006). Some other HMTs and related proteins, aberrations of 
which have been associated with HCC include NSD1, a methyltransferase acting on 
H3K36, and serving in context dependent transcriptional activation or repression; 
HP1, a protein which binds to methylated H3K9 and has a vital role on 
transcriptional silencing and heterochromatin formation; and finally RIZ1/PRDM2, a 
family of SET-domain containing methyltransferases, acting also on H3K9 (Wang 
GG, et al, 2007).  
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1.2.3.3 Histone 4 lysine 20 methylation 
Although histone H4 tail comprises 5 lysine residues, lysine 20 is the only one 
subject to methylation in mammals. H4K20 methylation is present in a wide variety 
of species, ranging from Schizosaccharomyces pombe (S. pombe) to human, with 
different levels of elaboration. In S. pombe, mono, di and trimethyl forms of H4K20 
are all established by the same enzyme: Set9. Nevertheless, in humans, H4K20 
methylation is more complex, resulting from the involvement of multiple 
methyltransferase enzymes, as well as multiple proteins which interact with H4 with 
different affinities depending on the degree of methylation (Yang H, et al, 2009). As 
can be judged from this level of elaboration, mono, di and trimethyl forms of H4K20 
are likely to play distinct roles in the cell.  
 
The cellular distribution of mono, di and trimethylated forms of H4K20 was 
analyzed in multiple settings such as normal and cancerous human cells, as well as 
drosophila, mouse and rat cells by using mass spectrometry. The analysis revealed 
that the dimethylated form of H4K20 was much more abundant than the other two in 
all cases. The results of the analysis on asynchronous HeLa (cervical cancer derived 
cell line) cells revealed a distribution of 10 % monomethylated, 80 % dimethylated 
and 5 % trimethylated H4K20 (Yang H, et al, 2009).  
 
The sub nuclear distribution of these forms is rather contradictory. H4K20me1 has 
usually been associated with condensed chromatin and the inactivated X 
chromosome, and it was proposed that this histone modification facilitates chromatin 
maturation (Trojer P, et al, 2006; Scharf AND; 2009). It was proposed that, 
L3MBTL1 protein binds preferentially to monomethylated and dimethylated H4K20, 
and assists compaction of the chromatin. This interaction was shown specifically on 
the promoter of Cyclin E gene, where L3MBTL1 recruitment by H4K20me1 was 
involved in silencing of this gene (Kalakonda N et al, 2008). Nevertheless, the 
conclusions of the high resolution histone modification profiling study by Barski et 
al contradicts with those findings, since according to this study, monomethylated 
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form of H4K20 was associated with gene activation (Barski A, et al, 2007). 
Similarly, the data about H4K20me2 sub nuclear distribution is also contradictory, 
which might be attributed to the ubiquitous disposition of this residue (Yang H, et al, 
2009).  
 
H4K20me3 has consistently been coupled with constitutive heterochromatin 
including centromeric and telomeric regions, satellite and long terminal repeats, as 
well as imprinted genes. Nevertheless, it was not reliably associated with a certain 
pattern of transcriptional activity, as exemplified by the failure of genome-wide chip 
approaches in forming such a relationship (Yang H, et al, 2009; Barski A, et al, 
2007). As mentioned earlier, Histone 4 lysine 20 trimethylation has been associated 
with various cancers, and loss of H4K20 trimethylation has been proposed to be a 
hallmark of cancer (Fraga MF, et al, 2005). Although trimethylated H4K20 levels are 
highly cell cycle dependent, transformed cells are subject to a specific loss. Liver 
tumors in rats induced by a methyl deficient diet showed a progressive decrease in 
H4K20 trimethylation (Pogribny IP, et al, 2006). Additionally, in human breast 
cancer cell lines, loss of H4K30me3 mark corresponded to more aggressive 
phenotypes (Tryndyak, VP, et al, 2006). Similarly, in a study of non-small cell lung 
cancer, cancer cells displayed loss of H4K20 trimethylation compared to normal lung 
cells (Broeck AVD, et al, 2008). 
 
1.2.3.4 Histone 4 lysine 20 methyltransferases and their cellular functions 
In human, there are three known enzymes which are known to act on H4K20 
methylation status. Set8 (alternatively known as Setd8, Pr-Set07 or KMT5A) is the 
enzyme which monomethylates the unmodified H4K20. Suv4-20h1 and Suv4-20h2 
enzymes use non methylated, or preferentially monomethylated H4K20 as a substrate 
and dimethylate or trimethylate this residue. Additional reports have argued the 
involvement of Ash1 and NSD1 enzymes in H4K20 methylation, but evidence is 
contradictory and insufficient (Yang H, et al, 2009). There are no identified 
demethylase enzymes that act on H4K20. 
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The activities of H4K20 methyltransferases are strictly regulated during the cell 
cycle, as well as the levels of methylated H4K20. As summarized in Figure 1.1, 
when newly synthesized H4 is joined into the chromatin structure during the S phase, 
it remains non methylated at K20 until almost the G2/M transition. With the peaking 
Set8 activity during the M phase, H4K20 starts to get monomethylated, which is 
followed by largely dimethylation and to a certain extent trimethylation by Suv4-20 
activity (Yang H, et al, 2009; Trojer P, et al, 2006). Despite this paradigm, some 
reports have demonstrated that Set8 activity is required for cell cycle progression, 
especially in the S phase (Jorgensen S et. al, 2007; Yin, Y et al, 2008). It is possible 
however that Set8 might play its cell cycle related roles through other substrates, as 
evidenced by the identification of p53 as a Set8 substrate (Shi X, et al, 2007). 
 
 
Figure 1.1: Cell cycle dependency of Set8 and Suv4-20 activities. (Adapted from Yang H, et al, 
2009).
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CHAPTER 2. OBJECTIVES AND RATIONALE 
 
Despite the high mortality rate and prevalence of hepatocellular carcinoma, the 
available treatment options are insufficient, and there are numerous things about the 
pathogenesis of HCC waiting to be unraveled (Farazi PA, et al, 2006). Understanding 
those mechanisms, and utilizing them against HCC presents challenges. In this 
respect, epigenetics is a newly emerging field with lots of evidence showing the 
relevance and importance of several epigenetic phenomena in cancer pathogenesis, 
including HCC; an important example is the development of liver tumors in rodents 
fed with a methyl deficient diet (Pogribny IP, et al, 2006).  
 
In a previous study performed by our group, samples from normal, cirrhotic and HCC 
tissues; together with senescent and immortal HuH-7 clones, were subjected to 
microarray analysis. According to the results of this study, epigenetic players, 
specifically histone modifying enzymes turned out to be promising factors that might 
be involved in HCC pathogenesis (unpublished data). Considering these facts, the 
question that if different histone methylation marks and histone modifying enzymes 
play roles in HCC pathogenesis came into being. Therefore, in this study, we first 
screened global levels of several histone methylation marks in immortal and senescent 
HCC cell lines. Following the identification of a marked difference of H4K20me3 
levels between well differentiated and poorly differentiated HCC cell lines, and the 
consistent literature evidence showing the involvement of this residue in various 
cancer types (Yang H, et al, 2009), we decided to concentrate on trimethylated 
H4K20, and the methyltransferase enzymes which function in formation of this 
histone mark. In this context, a detailed analysis of all the transcript variants of all 
three enzymes involved in the H4K20 methylation process was performed. Set8 
monomethyl transferase enzyme was the most prominent candidate that could play a 
role in HCC pathogenesis, consequently we tried to address its involvement in HCC 
development via overexpression and knockdown studies. The obtained results are 
presented and discussed in the following chapters. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 MATERIALS 
 
3.1.1 Reagents 
Most of the chemicals used in the laboratory were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and Merck (Darmstadt, Germany). Additionally, Bradford reagent, 
Haematoxylin, Ethanol and Methanol were also from Sigma-Aldrich. ECL and ECL+ 
Western blot detection kits were from Amersham Pharmacia Biotech Ltd. 
(Buckinghamshire, UK). Fluorescent mounting medium was from Dako. Ponceau S 
and DMSO were from Applichem Biochemica (Darmstadt, Germany). X-Gal was 
from MBI Fermentas GmbH (Germany). Total RNA isolation kit: Nucleospin RNA II 
was from Macherey-Nagel (Duren, Germany). Standard agarose was from Sigma 
Biosciences (St. Louis, MO, USA). Purified recombinant human TGF-β1 was from 
R&D Systems (Minneapolis, USA). 
 
3.1.2 PCR and cDNA synthesis reagents 
cDNA synthesis was performed using Fermentas RevertAid First Strand cDNA 
synthesis kit (MBI Fermentas, Leon-Rot, Germany). Polymerase Chain Reaction 
(PCR) reagents; 10X Taq DNA Polymerase Buffer (+(NH4)2SO4, -MgCl2), Taq DNA 
Polymerase, 2 mM dNTP, 25 mM MgCl2, were also purchased from Fermentas. 
DyNAmo HS SYBR Green qPCR Kit F-410 from Finnzymes was used for 
quantitative PCR reactions. 
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3.1.3 Nucleic acids and oligonucleotides 
DNA molecular weight markers and 6x gel loading buffer were purchased from 
Fermentas. The primers used in PCR reactions were synthesized by İONTEK 
(Istanbul, Turkey). Ex-T8950-Lv06 (Set8 plasmid) was purchased from GeneCopoeia 
company (USA). Set8 and control siRNAs were synthesized by Eurogentec 
(Belgium). 
 
3.1.4 Electrophoresis, photography and spectrophotometer 
Horizontal electrophoresis was done using Thermo Electron Corporation. Power 
supplies Power-PAC200 and Power-PAC300, and the analysis software for agarose 
gel imaging were from Bio Rad Laboratories (CA, USA). Spectrophotometer used in 
Bradford assay for protein concentration measurements was Beckman Du640, from 
Beckman Instruments Inc. (CA, USA). NanoDrop used for nucleic acid concentration 
measurements was from Thermo Scientific (Wilmington, USA). 
 
 3.1.5 Cell culture reagents and materials 
For cultivation of cell lines, Dulbecco’s modified Eagle’s medium (DMEM) and 
Roswell Park Memorial Institute (RPMI) 1640 medium were purchased from GIBCO 
(Invitrogen, Carlsbad, CA, USA). Additionally, Optimem medium for transfection,  
penicillin/streptomycin solution, trypsin-EDTA, fetal bovine serum (FBS), L-
glutamine and Geneticin-G418 sulphate were also from GIBCO. All cell culture 
plastic ware (flasks, petri dishes, plates, cryovials) were from Corning Life Sciences 
Incorporated (USA). Serological pipettes and sealed-cap polycarbonate centrifuge 
tubes were from Costar Corporation (Cambridge, UK). Lipofectamine 2000, and 
Lipofectamine RNAimax were also from Invitrogen.  
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 3.1.6 Antibodies 
Working dilutions and sources for all the antibodies used in different experiments are 
given in Table 3.1. 
Antibody Company and catalog 
number 
Western Blot 
working dilution 
Immunostaining 
working dilution 
H3K4me3 (rabbit polyclonal) Abcam, ab8580 - 1:1000 (IP) 
H3K9me3 (rabbit antiserum) Upstate, 07-523 - 1:1000 (IP) 
H3K27me3 (rabbit polyclonal) Upstate, 07-449 - 1:1000 (IP) 
H3K36me3 (rabbit polyclonal) Abcam, ab9050 - 1:1000 (IP) 
H3R2me2 (rabbit polyclonal) Upstate, 07-585 - 1:600 (IP) 
H3R17me2 (rabbit polyclonal) Abcam, ab8284 - 1:900 (IP) 
H3 (mouse monoclonal) Abcam, ab24834 1:1000 - 
H4K20me3 (rabbit polyclonal) Upstate, 07-463 1:2000 1:500 (IP) 
H4K20me1 (rabbit polyclonal) Abcam, ab9051 1:5000 1:200 (FC) 
HA-tag (mouse monoclonal) Covance, MMS-101P 1:500 - 
Calnexin (rabbit, polyclonal) Sigma, C4731 1:5000 - 
BrdU DAKO, M0744 - 1:500 (IF) 
Anti-mouse-HRP Sigma, A0168 1:5000 - 
Anti-rabbit-HRP Sigma, 6154 1:5000 - 
Anti-rabbit-Alexa Fluor 488 Invitrogen, A11034 - 1:100 (FC) 
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Anti-mouse-Alexa Fluor 568 Invitrogen, A11031 - 1:750 (IF) 
Rabbit polyclonal IgG  (isotype 
control) 
Abcam, ab27472 - 1:1 (FC) 
 
Table 3.1: Antibody dilutions. IP: immunoperoxidase staining, IF: immunofluorescent staining, FC: 
flow cytometry. 
 
3.2 SOLUTIONS AND MEDIA 
 
3.2.1 General and cell culture solutions 
50x Tris Acetate EDTA (TAE):  242 g Tris base, 57,1 ml glacial acetic 
acid, 18,6 g EDTA in 1 liter ddH2O (Working dilution is 1x). 
Ethidium bromide:    10 mg/ml stock is dissolved in water 
(Working solution is 30 ng/ml). 
10x Phosphate buffered saline (PBS): 80 g NaCl, 2 g KCl, 14,4 g Na2HPO4, 2,4 
g KH2PO4 in 1 liter ddH2O (Working dilution is 1x, autoclaved for use in cell 
culture).  
DMEM/RPMI 1640 working medium: 10% Fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 1% Non-essential amino acids were added to obtain complete 
medium. 
 
3.2.2 Sodium Deodecyl Sulphate (SDS) – Polyacrylamide Gel Electrophoresis 
(PAGE) and immunoblotting materials and solutions 
NuPAGE NOVEX pre-cast gel system from Invitrogen (CA, USA) was employed for 
running denaturing gels. 4-12 % gradient or 12 % Bis-Tris mini gels were used with 
either MES or MOPS running buffer, which were also purchased from Invitrogen. 
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4x sample loading buffer, 10x denaturing agent and antioxidant were also from 
Invitrogen, and they were used according to the manufacturer’s protocols.  
20x transfer buffer was also from Invitrogen, it was diluted to 1x working 
concentration, and used with 10 % methanol. 
NP-40 lysis buffer:    150 mM NaCl, 50 mM TrisHCl (pH 8.0), 
1 % NP-40, 0,1 % SDS, 1x protease inhibitor cocktail (from 25x stock) in ddH2O. 
10x Tris buffered saline (TBS):  12,19 g Trisma base, 87,76 g NaCl in 1 
liter ddH2O, pH is adjusted to 8 (Working dilution is 1x). 
TBS-tween (TBS-T):    0,2 % Tween-20 was dissolved in 1x 
TBS. 
Ponceau S solution:    0,1 % (w/v) Ponceau, 5 % (v/v) acetic 
acid in ddH2O. 
Blocking solution:    5 % (w/v) non-fat dry milk was 
dissolved in 0,2 % TBS-T. 
 
3.2.3 Immunoperoxidase and immunofluorescence solutions 
Immunoperoxidase blocking solution: 10 % FBS, 0,1% Triton-X in 1x PBS. 
Immunofluorescence blocking solution: 10 % FBS in 0,2% PST-Tween 20. 
4’, 6-diamino-2-phenylindole (DAPI): 0,1-1 μg/ml (Working solution in 
ddH2O) 
DAKO EnVision
TM
 system was used for immunoperoxidase staining (Denmark). 
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3.2.4 Senescence associated β-galactosidase (SABG) assay solutions 
SABG buffer:     40 mM citric acid/sodium phosphate 
buffer (pH 6.0), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 
mM NaCl, 2 mM MgCl2, 1 mg/ml X-gal in ddH2O. pH is adjusted to 6.0, and the 
solution is filtered prior to use. 
 
3.2.5 BrdU incorporation assay solutions 
BrdU stock solution:    10 mg/ml BrdU in ddH2O (Working 
solution is 30 μM) 
 
3.3 METHODS 
 
3.3.1 General methods 
 
3.3.1.1 Quantification and qualification of nucleic acids 
NanoDrop ND-1000 Full-spectrum UV/Vis spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE, USA) was employed in order to quantify DNA and RNA. 
Quality and purity of nucleic acids were determined by calculation of OD260 to OD280 
ratio. 
 
3.3.1.2 Agarose gel electrophoresis of nucleic acids 
DNA fragments obtained by PCR were fractioned by horizontal electrophoresis 
apparatus. Agarose gels were prepared using 1x TAE buffer; agarose concentration 
was calculated as weight / volume, and agarose was dissolved completely in 1x TAE 
by heating in the microwave oven.  Ethidium bromide was added to a final 
concentration of 30 μg/ml after some cooling. All PCR products were less than 1 kb, 
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therefore they were separated on 2 % agarose gel with 1x TAE running buffer. 
Samples were prepared by the addition of 6x loading buffer from Fermentas to a final 
concentration of 1x. Gels were usually run at 110 V, with different time periods 
depending on the size of the product. Bands were visualized under UV light, and 
fragment sizes were estimated using Fermentas Gene Ruler DNA ladders, especially 
100 bp ladder and 1 kb ladder were used for PCR products.  
 
3.3.1.3 Computer, software and database tools 
The sequences and all other information about the genes were obtained from NCBI 
(National Center for Biotechnology Information) website at: 
http://www.ncbi.nlm.nih.gov/, and Ensembl Genome Browser website at: 
http://www.ensembl.org/index.html. Primers were designed using the online web tool 
Primer3, provided by Steve Rozen and Helen J. Skaletsky (2000) at: 
http://frodo.wi.mit.edu/primer3/. In silico PCR to confirm that the primers hit only a 
single location in the genome was performed using UCSC (University of California, 
Santa Cruz) Genome Bioinformatics website, in silico PCR online tool at: 
http://genome.ucsc.edu/. The alignment of nucleic acid or protein sequences were 
performed by using Clustal W algorithm, provided by SDSC (San Diego 
Supercomputer Center) Biology Workbench website at: http://workbench.sdsc.edu/. 
Information about proteins was retrieved from Uniprot (Universal Protein Resource) 
database at: http://www.uniprot.org/.  
 
3.3.2 Cell and tissue culture techniques 
 
3.3.2.1 Cell lines and stable clones 
15 HCC derived cell lines were used in this study, which were: HuH-7, Hep40, 
HepG2, Hep3B, Hep3B-TR, PLC/PRF/5, SNU-182, SNU-387, SNU-398, SNU-423, 
SNU-449, SNU-475, Mahlavu, FOCUS, SK-HEP-1. These cell lines were cultured as 
previously (Cagatay T. and Ozturk M, 2002). Briefly, HuH-7, Hep40, HepG2, 
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Hep3B, Hep3B-TR, PLC/PRF/5, , Mahlavu, FOCUS and SK-HEP-1cell lines were 
cultured in DMEM working medium, and all the SNU cell lines were cultured in 
RPMI 1640 working medium. SNU-475 derived stable clone SNU-475-Set8 was 
selected by G-418 antibiotic after 1 week of lentiviral infection. G-418 selection was 
performed with a concentration of 400 μg/ml in complete medium. G418 was 
renewed every 3 days. After 2 weeks of G-418 selection, selected cells were 
maintained in the presence of 100 μg/ml G-418 and G-418 was withdrawn from the 
medium when experiments are set-up with this clone. When a certain number of cells 
are needed, cells were counted by using a haemocytometer after trypsinization and 
resuspension in growth medium. 
 
3.3.2.2 Thawing cells 
Frozen cells in cryovials from liquid nitrogen or  -80ºC freezer were taken and 
immediately put on ice. Vials were placed in 37 ºC water bath and waited 1-2 min to 
thaw. Before the cells were completely thawed, the suspension was taken into 15 ml 
sterile centrifuge tube with approximately 10 ml growth medium and resuspended. 
Cells were centrifuged at 1500 rpm for 3 minutes, supernatant was discarded, and the 
pellet was resuspended in 10 ml fresh growth medium to be placed into 75 cm
2
 flasks 
or 100 mm dishes. Flasks or dishes were rocked back and forth gently in order to 
allow the cell suspension to mix, and they were incubated overnight at a 37ºC 
humidified incubator with 5 % CO2. The next day, cells were washed with 1x PBS, 
and culture mediums were replaced with fresh growth mediums. 
 
3.3.2.3 Growth conditions of cells 
HCC cell lines were cultured in DMEM or RPMI 1640 mediums supplemented with 
10 % FBS, 1 % penicillin/streptomycin and 1 % Non-essential amino acids as 
specified previously. Cells were incubated in humidified 37ºC incubators with 5 % 
CO2 in the air. Cells were passaged regularly, approximately 2-3 days apart, 
depending on the cell type, but before reaching confluency each time. When 
passaging cells, old growth medium was aspirated, cells were washed with 1x PBS 
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once, after aspirating the PBS, trypsin-EDTA solution was added on to the cells with 
the amount depending on the size of the culture flask, usually 1-2 ml for 100 mm 
dishes were used. After waiting 1-2 minutes when trypsin removed the monolayer of 
the cells from the surface, fresh medium was added and cells were collected by 
pipetting up and down with serological pipettes several times, and therefore mixed 
thoroughly. Afterwards, cells were re-seeded on fresh dishes or flasks with the 
required dilutions. All mediums, 1x PBS and trypsin-EDTA were stored at +4ºC 
refrigerator. FBS stock solutions were stored at -20ºC refrigerators, thawed in 37ºC 
water bath, heat-inactivated at 56ºC for 30 minutes, then aliquoted into sterile 50 ml 
centrifuge tubes and stored at -20ºC, they were also filter-sterilized prior to use. All 
solutions and media were warmed at 37ºC water bath prior to use. 
 
3.3.2.4 Cryopreservation of cells 
Cells were harvested when they were approximately 60 % confluent, at their 
exponential growth phase. Cells were collected by trypsinization, neutralized by 
growth medium, centrifuged at 1500 rpm for 3 minutes and the supernatant was 
aspirated. The pellet was resuspended in freezing medium, which contained 8 % FBS 
and 8 % DMSO in growth medium, at a concentration of approximately 4 x 10
6
 
cells/ml. 1 ml of these cells were stored in cryovials, these were immediately placed at 
-20ºC for 1 hour, then stored at -80ºC overnight, then transferred into liquid nitrogen 
tanks for long term storage. 
 
3.3.2.5 Transient transfection of eukaryotic cells using Lipofectamine 2000 
reagent 
Plasmid DNA transfection of cells were performed by using Lipofectamine 2000 
reagent from Invitrogen (CA, USA), according to the manufacturer’s protocols, with a 
DNA:Lipofectamine ratio of 1:3. OPTI-MEM reduced serum medium from GIBCO, 
Invitrogen was used for transfection experiments.  
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3.3.2.6 Transient transfection of eukaryotic cells using Lipofectamine RNAi-max 
reagent 
Cells were transfected with siRNAs using Lipofectamine RNAi-max reagent from 
Invitrogen according to the manufacturer’s protocols. OPTI-MEM reduced serum 
medium from GIBCO, Invitrogen was again used for transfection experiments. Final 
siRNA concentrations were determined by optimization. siRNA sequences for Set8 
gene were obtained from the literature (Huen MSY, et al, 2008), similarly like control 
siRNAs (Shi X, et al, 2007), and synthesized by Eurogentec company (Belgium). List 
and sequences of the siRNAs used in this study are given in Table 3.2. 
siRNA Sequence 
Set8-siRNA1 Sense GCA-ACU-AGA-GAG-ACA-AAU-CTT 
Set8-siRNA1 Antisense GAU-UUG-UCU-CUC-UAG-UUG-CTT 
Set8-siRNA2 Sense GAU-UGA-AAG-UGG-GAA-GGA-ATT 
Set8-siRNA2 Antisense UUC-CUU-CCC-ACU-UUC-AAU-CTT 
Set8-control siRNA UGG-UUU-ACA-UGU-CGA-CUA-ATT 
Set8-control siRNA UUA-GUC-GAC-AUG-UAA-ACC-ATT 
Table 3.2: siRNA sequences 
 
3.3.2.7 Lentiviral Infection of eukaryotic cells 
Lentiviral infection of eukaryotic cells was performed using GeneCopoeia Lenti-Pac 
FIV Expression Packaging Kit, according to the manufacturer’s protocol. Briefly; on 
Day 0 packaging cells were seeded (HEK 293 cells) on 100 mm dishes. On Day 1, 
packaging cells were transfected with the target vector (Ex-T8950-Lv06 in this case) 
and the Lenti-Pac packaging mix using Endofectin transfection reagent for 14 hours at 
a 37ºC incubator. After changing the medium with growth medium supplemented 
with 5 % FBS and titer boost reagent, incubation was continued for an additional 24 
hours, in order to let the virus particles form. Virus particles were harvested from the 
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supernatant of the packaging cells, filtered with a 0,2 μm filter. 1,5 ml of the collected 
virus containing medium was added on each well of cells to be infected (SNU-475 in 
this case) in 6-well plates. The next day, their medium was changed with normal 
growth medium, and the incubation was continued with normal growth medium until 
the cells approached confluency. Then they were transferred to 25 cm
2
 flasks, and G-
418 antibiotic selection was started within a week. 
 
3.3.3 Extraction of total RNA from cultured cells and tissue samples 
Total RNA was extracted from cultured cells and tissue samples by using Macherey-
Nagel (MN) Nucleospin RNA II kit (MN, Duren, Germany) according to the 
manufacturer’s protocol. When RNA was isolated from liver tissues, samples were 
first homogenized by pestle and mortar  in the presence of liquid nitrogen, then the 
procedure was continued with the MN kit.  
 
3.3.4 First strand cDNA synthesis 
First strand cNDA was synthesized from total RNA using Fermentas RevertAid 
cDNA synthesis kit (MBI Fermentas, Germany) according to the manufacturer’s 
protocols. For RNA samples from cultured cells, reactions were primed with 
Oligo(dT)18 primers, and for RNA samples from  tissues, reactions were primed with 
a 1:1 mixture of Oligo(dT)18 and Random Hexamer primers. First strand cDNA 
products obtained from this kit were used directly as templates for RT-PCR reactions. 
First strand cDNA was synthesized from 2 μg RNA for cultured cell samples, and 
from 4 μg RNA for tissue samples, in total 30 μl volume, and 2 μl of this product was 
used as RT-PCR template. In order to check for genomic DNA contamination, RT (-) 
cDNA samples were also synthesized from total RNA, where no reverse transcriptase 
enzyme was added in the reaction, therefore the only DNA template obtained was 
from the possible genomic DNA contamination. 
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3.3.5 Primer design for gene expression analysis by RT-PCR  
When primers were designed for RT-PCR reactions, forward and reverse primers 
were positioned on different exons. That way, it was ensured that product size would 
be much higher if there was amplification from genomic DNA. Difference between 
the melting temperatures of forward and reverse primers were set to be no greater than 
1ºC, and the GC contents were no greater than 60 %. Amplicon sizes were variable; in 
order to differentiate between different transcript variants, different amplicon sizes 
were used. All primers used for gene expression analysis are listed in Table 3.3. 
Primer Sequence Tm (ºC) 
Number 
of cycles 
Suv4-20h1, Variant 1 
F1: TGGAGATGGGTTCTTTGGAG 
R1: GCTTTGCAGGCTTCTTCAGT 
58 30 
Suv4-20h1, Variant 2 
F1: TGGAGATGGGTTCTTTGGAG 
R2: TGAAGTGCAGCCAAAGCTC 
56 35 
Suv4-20h2, Variants 1 & 2 
F1: CTCACCTGCTCCTGCTCTCT 
R2: TCCTGATTCCTTCTGCTTCC 
63 35 
Suv4-20h2, Variant 3 
F1: CTCACCTGCTCCTGCTCTCT 
R1: CTTGCGGGTTGAGTACATGA 
58 35 
Set8, Variants 1 & 4 
F1: AGAGGCAGGAAGATGTCCAA 
R2: TGCCCGGTAAATACGTTCTC 
60 30 
Set8, Variant 3 
F2: CAGTCACCCTGAGAGAAGTCCT 
R1: TTCCTGGCGTCTTTGATCTT 
63 35 
Set8, Full length  
F1: AGAGGCAGGAAGATGTCCAA 
R3: GTCCTTTGAAGAAGGGAAAGTG 
58 30 
GAPDH 
F: GGCTGAGAACGGGAAGCTTGTCAT 
R: CAGCCTTCTCCATGGTGGTGAAGA 
60 21 
Table 3.3: Primers and working conditions 
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3.3.6 Gene expression analysis by semi-quantitative RT-PCR 
Firstly, before starting the gene expression analysis by RT-PCR, possible genomic 
DNA contamination was controlled by GAPDH RT-PCR. GAPDH primers were 
designed so that they amplify a 151 bp fragment from cDNA, but a 250 bp fragment 
from genomic DNA. Additionally, RT (-) cDNAs were also employed in order to 
control for possible genomic DNA contamination. When semi-quantitative RT-PCR 
reactions were set up, firstly 2 μl of each sample were used to setup GAPDH RT-PCR 
in order to do normalization. After GAPDH products were run on an agarose gel and 
band intensities were compared, adjustments for the cDNA amount to be used were 
made (if required). After then, the GAPDH RT-PCR reaction and the RT-PCR 
reaction for the gene of interest were set up with the adjusted amounts of cDNAs. 
 
In order to determine the optimum cycle number for each semi-quantitative RT-PCR 
reaction, PCR reactions with different cycle numbers were set up and the minimum 
cycle number that allows the visualization of the desired product were selected. 
 
3.3.7 Gene expression analysis by quantitative RT-PCR 
Stratagene Mx 3005P system was used for quantitative PCR analysis. Reactions were 
performed using DyNAmo HS SYBR Green qPCR Kit F-410 from Finnzymes. 
Reactions were set up in a total volume of 25 μl with 2 μl cDNA for each sample. 
Reactions were started with 10 minutes initial denaturation at 95ºC, then amplification 
was performed with 40 to 45 cycles of: 30 seconds at 95ºC, 30 seconds at Tm of 
primer pair, 30 seconds at 72ºC. Samples were analyzed in triplicates, GAPDH 
reactions were performed in duplicates. Product purity was addressed by a 
dissociation curve. For each primer pair, prior to analysis, standard curve for the 
primer efficiency was obtained by setting up multiple reactions with 2 fold dilutions 
of selected cDNAs from 1 to 1:256. Primer efficiency was then calculated as: E = 2
(-
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1/slope)
. When fold changes were calculated from the obtained data, ΔΔCt method was 
employed, and the primer efficiencies were also involved in the formula.  
 
3.3.8 Crude total protein extraction from cultured cells 
HCC derived cell lines were collected either by trypsinization and pelleted, or 
collected by scraping by a scraper in the presence of lysis buffer in order to extract 
protein. NP-40 lysis buffer was used for protein extraction procedures. Lysis was 
performed by resuspending cell pellets in twice their volume of lysis buffer, and 
incubating in ice for 30 minutes with gentle mixing every 5 minutes. Then the lysates 
were centrifuged at 11000 g for 20 minutes at +4ºC. Total protein in the supernatant 
form was then collected and stored at -20ºC.  
 
3.3.9 Acid extraction of histones 
In order to obtain histone extracts from cultured cells, acid extraction method was 
employed which was previously described (Shechter D, et al, 2007). Briefly, cells 
were harvested by trypsinization, lysed in triton extraction buffer (1x PBS with 0,5 % 
Triton-X 100 (v/v),  0,02 % (w/v) NaN3 and 1x protease inhibitor cocktail) for 10 
minutes on ice. Lysate was then centrifuged at 2000 rpm for 10 minutes at +4ºC and 
the supernatant was discarded. The pellet was washed with triton extraction buffer 
once more, and the histones were extracted in 0,2 N HCl overnight at +4ºC on rotator. 
The next day, samples were centrifuged at 2000 rpm for 10 minutes at +4ºC, the 
supernatant contained the histones, they were stored at -20ºC. 
 
3.3.10 Western blotting 
Firstly, in order to measure the concentration of protein lysates, the conventional 
Bradford assay was used. Sample protein concentrations were determined by 
comparing the absorbance values to a standard curve obtained by the absorbance 
values of 2-fold serial dilutions of bovine serum albumin (BSA) protein of a known 
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concentration. When mixed with the Bradford reagent, proteins formed blue color, 
which was measured by spectrophotometer at 595 nm. After quantification, equal 
amounts of cell lysates were used to prepare protein samples to be loaded on gels. 
Protein samples were prepared by mixing with 4x NuPAGE LDS Sample Buffer from 
Invitrogen, 10x denaturing agent from Invitrogen, and ddH2O to complete the volume. 
The samples were then heated at 70ºC for 10 minutes. 
 
NOVEX NuPAGE system from Invitrogen was used for running gels and transferring 
proteins to nitrocellulose membranes,  according to the manufacturer’s protocols. 4-12 
% gradient Bis-Tris mini gels were used when working with whole cell lysates, and 
12 % Bis-Tris mini gels were used when working with histone extracts, for better 
separation. The running buffers used were MES for histone gels, and MOPS or MES 
for whole cell lysate gels, depending on the size of the proteins that were being 
studied. The transfer buffer was used with 10 % methanol, and the gels were 
transferred to nitrocellulose membranes.  
 
The obtained membranes with transferred proteins were blocked with either non fat 
dry milk or BSA with a 5 % concentration in 0,2 % TBS-T, depending on the 
suggestions for the specific antibodies used. Blocking was done for 1 hour at room 
temperature. Probing with the primary antibodies were either done at room 
temperature for one hour, or overnight at +4ºC. Membranes were washed for half an 
hour in 0,2 % TBS-T and incubated with HRP conjugated secondary antibodies for 1 
hour at room temperature. After an additional wash of half an hour, chemiluminescent 
detection was performed by using ECL or ECL+ western blot detection kits from 
Amersham (UK), according to the manufacturer’s protocols. X-ray films were 
exposed to the emitted chemiluminescence, duration depending on the specific 
antibody. 
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3.3.11 Immunoperoxidase staining 
Cells were seeded in 6-well cell culture plates on autoclave-sterilized coverslips with 
such a confluency that they will be sub-confluent on the day of immunoperoxidase 
staining. Depending on the growth rate, size and morphology of each cell line, the 
exact number of seeded cells was variable. Cells were washed with 1x PBS, fixed 
with 4 % Formaldehyde for 10 minutes, washed once again with 1x PBS and 
permeabilized with 0,5 % Saponin, 0,3 % Triton-X in 1x PBS for 10 minutes. After 
washing three times with 1x PBS, cells were blocked with 10 % FBS, 0,1 % Triton-X 
in 1x PBS for 1 hour at room temperature. Primary antibody incubation was done 1 
hour at room temperature, antibodies were prepared in 2 % FBS in 1x PBS, and were 
applied directly on coverslips. After washing once with 1x PBS and once with 1x PBS 
with 0,3 % Triton-X, secondary antibody (DAKO, anti mouse + anti rabbit pool) 
incubation was performed similarly. Cells were then stained with DAKO-DAB 
Chromogen solution for ~ 1 minute. The reaction was stopped with ddH2O, and 
counterstaining was performed by Mayer’s Haematoxylin for ~ 0,5 – 1 min. After 
final washes with ddH2O, coverslips were mounted on slides using 90 % glycerol, and 
the images were examined under light microscope (ZEISS). 
 
3.3.12 BrdU incorporation and immunofluorescence staining 
Sub-confluent cells seeded on coverslips were labeled with 30 μM thymidine analog 
BrdU for 2,5 hours prior to staining with anti-BrdU antibody by immunofluorescent 
staining. Cells were washed with 1x PBS twice, then fixed with 70 % cold ethanol for 
10 minutes. After washing with 1x PBS, cells were then incubated with 2 N HCl for 
20 minutes and washed again with 1x PBS three times. Blocking was performed with 
10 % FBS in 0,2 % PBS-Tween for 1 hour. Anti-BdrU primary antibody was prepared 
in blocking solution, and applied directly on coverslips. After washing with 0,2 % 
PBS-Tween three times, Alexa-568 secondary antibody was again applied directly on 
coverslips, for 1 hour. Cells were again washed with 0,2 % PBS-Tween three times, 
and nuclei were stained with DAPI for 1 minute. DAPI was washed with ddH2O, and 
the coverslips were mounted on slides using DAKO fluorescent mounting medium. 
Cells were visualized with fluorescent microscope, and merged images were 
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generated with two separate filters. Several areas were counted for DAPI stained cells 
and BrdU positive cells manually. 
 
3.3.13 SABG assay 
SABG assay was performed as described previously (Dimri GP, et al, 1995). Briefly, 
cells seeded on coverslips were washed with 1x PBS, fixed with 4 % Formaldehyde 
for 10 minutes, washed again once with 1x PBS. Then they were incubated in SABG 
buffer in a 37ºC, dark and CO2-free environment for ~18 hours. 
 
3.3.14 Flow cytometry of histone residues 
Cells were harvested by trypsinization, washed once with 1x PBS, and fixed with 4 % 
paraformaldehyde for 15 minutes at room temperature. Fixation was stopped by 
adding cold PBS, and paraformaldehyde was spinned off by centrifugation at 1500 
rpm for 3 minutes. Cells were then incubated in 5 % BSA, 0,1 % Triton-X in 1x PBS 
for 30 minutes, which was followed by washing with incubation buffer (5 % BSA in 
1x PBS) twice. 0,2 – 0,5 μg primary antibody was used for 1 million cells, similarly 
as the corresponding isotype control. Primary antibodies were prepared in incubation 
buffer, and incubation was done for 1 hour. After washing once with incubation 
buffer, cells were incubated with Alexa-Fluor-488 conjugated secondary antibodies; 2 
μg for 1 million cells, for 1 hour. Finally, cells were washed once with incubation 
buffer, and resuspended in 1x PBS.  Analysis was done using FACSCalibur Flow 
Cytometer (BD Biosciences, San Jose, CA) and Cell Quest 3.2 software. 
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3.3.15 Cellular growth rate measurements with Roche xCELLigence system 
Cells were seeded in E-96 plates special for the apparatus, according to the 
manufacturer’s protocols. The cell number to be seeded for the assay was optimized 
for the cell lines by performing the experiment with serial dilutions. For SNU-475, 
1000 or 2000 cells were seeded in a total of 200 μl. Cell indexes were retrieved every 
2 hours, for up to 160 hours, and calculations were done accordingly. All experiments 
were planned in triplicates, averages and standard deviations were calculated.  
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CHAPTER 4. RESULTS 
4.1. Histone Methylation  
 
4.1.1 Histone methylation levels in HCC cell lines 
Global levels of histone modifications that are candidates for playing a role in HCC 
development or senescence were screened by immunoperoxidase staining in the 
presence or absence of TGF-β induced senescence. In this study, 15 HCC cell lines 
are used, which are divided into two subtypes by our group (Yuzugullu H, et al, 
2009). These subtypes are: well differentiated and poorly differentiated, and the 
classification is based on characteristics such as the expression of differentiation 
markers like E-Cadherin and Vimentin, together with the expression of hepatocyte 
lineage markers. Well differentiated cell lines preserve their epithelial phenotype, and 
most of them respond to TGF-β treatment by undergoing senescence. Poorly 
differentiated cell lines are mesenchymal-like, in terms of their expression of 
mesenchymal markers, their high invasiveness and motility in comparison to well-
differentiated cell lines, and they do not respond to TGF-β treatment by undergoing 
senescence (Senturk, S et al, 2010). Well differentiated cell lines include: HuH-7, 
Hep40, HepG2, PLC/PRF/5 and Hep3B, whereas poorly differentiated cell lines 
include: SNU-182, SNU-387, SNU-398, SNU-449, SNU475, Mahlavu, SK-HEP-1 
and FOCUS.  
 
The analyzed histone methylation marks are: trimethylated histone H3 lysine 27 
(H3K27me3), trimethylated histone H3 lysine 4 (H3K4me3), trimethylated histone 
H3 lysine 9 (H3K9me3), trimethylated histone H3 lysine 36 (H3K36me3), 
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trimethylated histone H4 lysine 20 (H4K20me3), dimethylated histone H3 arginine 2 
(H3R2me2), and dimethylated histone H3 arginine 17 (H3R17me2). 
 
4.1.1.1 Histone H3 lysine 27 trimethylation in HCC cell lines 
Global levels of H3K27me3 were the first to be compared in well and poorly 
differentiated HCC cell lines in the presence and absence of TGF-β induced 
senescence. In order to induce senescence, cells were treated with 5 ng/ml TGF-β for 
72 hours, then TGF-β was withdrawn from the growth medium. On Day4 or Day8 of 
TGF-β treatment, senescent cells were marked with Senescence Associated β-
Galactosidase (SABG) assay, which was followed by immunoperoxidase staining 
with H3K27me3 antibody. Nuclear counterstaining was performed using 
haematoxylin. The results of these staining experiments are shown in Figure 4.1.1. 
 
Figure 4.1.1: Global levels of H3K27me3 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Cells were seeded in 6-well tissue 
culture plates on coverslips with such a confluency that they will be sub-confluent on Day 4 and Day 8, 
when the immunostaining experiments were performed. Immunostaining was performed as explained 
in the Materials and Methods section. In order to avoid bias, all pairs with 0 or 5 ng/ml TGF-β 
treatment were visualized and photographed under same lighting conditions using 40x objective. 
Example positive cell was shown with a red arrow, and example negative cell was shown with a black 
arrow. 
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Figure 4.1.1 (continued): Global levels of H3K27me3 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
 
As can be seen in the above figure, most of the cell lines stained positive for 
H3K27me3, with the exceptions of SNU-475, SK-HEP-1, FOCUS and maybe SNU-
423, which stained heterogeneously. However, we were unable to detect a significant 
change in global H3K27me3 levels in response to TGF-β induced senescence, when 
we compared the brown immunoperoxidase staining in senescent cells which are 
stained with SABG (light blue color) or immortal cells which are not stained with 
SABG. Poorly differentiated and well differentiated cells also did not seem to vary in 
terms of global levels of this histone mark. 
 
4.1.1.2 Histone H3 lysine 4 trimethylation in HCC cell lines 
Global H3K4me3 levels were analyzed in our 15 HCC cell lines similarly with 
immunoperoxidase staining. . In order to induce senescence, cells were treated with 5 
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ng/ml TGF-β for 72 hours, then TGF-β was withdrawn from the growth medium. On 
Day4 or Day8 of TGF-β treatment, cells were stained using H3K4me3 antibodies as 
described in the Materials and Methods section. Results of these immunostaining 
experiments are shown in Figure 4.1.2. 
 
 
Figure 4.1.2: Global levels of H3K4me3 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Cells were seeded in 6-well tissue 
culture plates on coverslips with such a confluency that they will be sub-confluent on Day 4 and Day 8, 
when the immunostaining experiments were performed. In order to avoid bias, all pairs with 0 or 5 
ng/ml TGF-β were visualized and photographed under same conditions using 40x objective. Example 
positive cell was shown with a red arrow, and example negative cell was shown with a black arrow. 
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Figure 4.1.2 (continued): Global levels of H3K4me3 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
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The results shown in Figure 4.1.2 indicate a strong global staining for H3K4me3 
residue for most of the cell lines, with the exceptions of SNU-387 and SNU-423 
which showed a slightly weaker and heterogeneous staining. In SNU-475, Day 4 
samples, TGF-β treatment seemed to result in a loss of H3K4 trimethylation in a 
heterogeneous manner, which was not observed in Day 8 samples. Mitotic cells 
stained strong in all cases in that cell line. Taken as a whole, H3K4me3 modification 
in HCC cell lines has a strongly positive pattern with some variations among cell 
types; however that does not seem to be affected strongly by TGF-β induced 
senescence. Differentiation status of cell lines also seems to be independent from the 
trimethylation status of H3K4. 
 
4.1.1.3 Histone H3 lysine 9 trimethylation in HCC cell lines 
Global levels of H3K9me3 were analyzed in our 15 HCC cell line panel in the 
absence or presence of TGF-β induced senescence. Experimental setting for cell 
seeding, TGF-β treatment, and immunoperoxidase staining is as described in the 
previous sections. Results of these immunoperoxidase staining experiments are shown 
in Figure 4.1.3. 
 
Figure 4.1.3: Global levels of H3K9me3 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Immunostaining experiments were 
done on Day 4 or Day 8 of 0 or 5 ng/ml TGF-β treatment. In order to avoid bias, all pairs with 0 or 5 
ng/ml TGF-β were visualized and photographed under same lighting conditions using 40x objective. 
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Figure 4.1.3 (continued): Global levels of H3K9me3 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
 
According to the results shown in Figure 4.1.3, H3K9me3 showed a strong nuclear 
staining pattern in most of the cell lines with some exceptions. PLC/PRF/5 contained 
a cytoplasmic stained fraction in addition to its nuclear positivity in Day 8 samples, 
and this was increased with TGF-β treatment. Cytoplasmic staining could be an 
artifact resulting from the staining protocol when nuclear localization of histones is 
considered. In SNU-387 and SNU-423 cell lines, nuclear staining patterns are 
observed as weak to moderately stained. In Mahlavu and SK-HEP-1 Day 8 samples, 
H3K9me3 staining seemed to be weaker in  TGF-β positive conditions.  
 
4.1.1.4 Histone H3 lysine 36 trimethylation in HCC cell lines 
H3K36me3 levels in HCC cell lines are again determined by immunoperoxidase 
staining in the presence or absence of  72 hour 5 ng/ml TGF-β treatment. Cells were 
stained with antibodies specific to H3K36me3 modification to assess the global levels 
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of this histone mark on Day 4 or Day 8 of TGF-β treatment as described in the 
previous sections. Results of these staining experiments are shown in Figure 4.1.4. 
 
 
Figure 4.1.4: Global levels of H3K36me3 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Immunostaining experiments were 
done on Day 4 or Day 8 of 0 or 5 ng/ml TGF-β treatment. In order to avoid bias, all pairs with 0 or 5 
ng/ml TGF-β were visualized and photographed under same lighting conditions using 40x objective.  
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Figure 4.1.4 (continued): Global levels of H3K36me3 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
 
As shown in Figure 4.1.4, H3K36me3 staining in HCC cell lines revealed mostly a 
cytoplasmic staining pattern with a nuclear staining pattern that changed from weak to 
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strong. Considering the nuclear localization of histones, the cytoplasmic staining is 
most likely false positive, that might have resulted from nonspecific binding of the 
antibody. Therefore, it is not completely reliable to make comparisons or to draw 
conclusions from this data. 
 
4.1.1.5 Histone H3 arginine 2 dimethylation in HCC cell lines 
Global H3R2me2 levels in HCC cell lines were analyzed by immunoperoxidase 
staining experiments in the absence or presence of TGF-β induced senescence. 
Senescence was induced in specific cell lines as described in previous sections and 
was previously analyzed by SABG assay, therefore SABG assay was not repeated for 
each specific histone methylation mark. Results of these experiments are shown in 
Figure 4.1.5. 
 
 
Figure 4.1.5: Global levels of H3R2me2 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Immunostaining experiments were 
done on Day 4 or Day 8 of 0 or 5 ng/ml TGF-β treatment. In order to avoid bias, all pairs with 0 or 5 
ng/ml TGF-β were visualized and photographed under same lighting conditions using 40x objective.  
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Figure 4.1.5 (continued): Global levels of H3R2me2 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
 
As seen in Figure 4.1.5, most of the cells were stained positive for global H3R2me2, 
with some amount of variation between cell lines that ranged from moderately 
positive to weakly positive. Slightly cytoplasmic stained parts are considered to be 
nonspecific. In HuH-7 cell line, H3R2me2 levels were reduced in TGF-β treated 
sample. In SNU-449 and Mahlavu cell lines, H3R2me2 is weakly stained, together 
with strongly stained mitotic cells. Other than those specified, the overall pattern of 
H3R2me2 staining is similar in all cell lines, irrespective of TGF-β induced 
senescence.  
 
4.1.1.6 Histone H3 arginine 17 dimethylation in HCC cell lines 
All cell lines were also tested against global levels of H3R17me2, similarly in the 
presence or absence of 5 ng/ml TGF-β treatment which induces senescence in most 
well-differentiated HCC cell lines. Immunoperoxidase staining experiments were 
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performed similarly on Day 4 or Day 8 of TGF-β treatment. The results of those 
experiments are shown in Figure 4.1.6 
 
 
Figure 4.1.6: Global levels of H3R17me2 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Immunostaining experiments were 
done on Day 4 or Day 8 of 0 or 5 ng/ml TGF-β treatment. In order to avoid bias, all pairs with 0 or 5 
ng/ml TGF-β were visualized and photographed under same lighting conditions using 40x objective.  
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Figure 4.1.6 (continued): Global levels of H3R17me2 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
 
According to the results shown in Figure 4.1.6, most of the cell lines exhibited a 
strongly positive nuclear staining in both TGF-β conditions. PLC/PRF/5 cell line 
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responded to TGF-β treatment which appeared to result in a heterogeneous 
H3R17me2 staining in Day 8 samples. SNU-423 and SK-HEP-1 cell lines exhibited 
heterogeneous staining in all cases. SNU-449 cell line was stained heterogeneously, 
which turned into full positive staining in the TGF-β positive case. 
 
4.1.1.7 Histone H4 lysine 20 trimethylation in HCC cell lines 
As previously mentioned, Histone 4 lysine 20 trimethylation has been associated with 
other cancers in the literature. Loss of H4K20 trimethylation has been proposed to be 
a hallmark of cancer (Fraga MF, et al, 2005). Although trimethylated H4K20 levels 
are highly cell cycle dependent, transformed cells are subject to a specific loss. Liver 
tumors in rats induced by a methyl deficient diet showed a progressive decrease in 
H4K20 trimethylation (Pogribny IP, et al, 2006).  Additionally, in human breast 
cancer cell lines, loss of H4K30me3 mark corresponded to more aggressive 
phenotypes (Tryndyak, VP, et al, 2006). Similarly, in a study of non-small cell lung 
cancer, cancer cells displayed loss of H4K20 trimethylation compared to normal lung 
cells (Broeck AVD, et al, 2008). 
 
Since well and poorly differentiated HCC cell lines represent early and advanced 
stages of HCC, it was likely that these two HCC cell line subtypes could exhibit 
differences between H4K20me3 methylation status.  Therefore, we decided to screen 
our cell line panel for the global H4K20me3 levels of cell lines using again 
immunoperoxidase staining method. TGF-β induced senescence model is also 
employed in this experiment. Cells were seeded in 6-well tissue culture plates on 
coverslips. The next day, they were subjected to 72 hours of 0 or 5 ng/ml TGF-β 
treatment. The immunostaining experiments were performed on Day 4 or Day 8 of 
TGF-β treatment. Results of these experiments are shown in Figure 4.1.7. 
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Figure 4.1.7: Global levels of H4K20me3 in HCC cell lines in the presence or absence of TGF-β 
induced senescence; determined by immunoperoxidase staining. Immunostaining experiments were 
done on Day 4 or Day 8 of 0 or 5 ng/ml TGF-β treatment. In order to avoid bias, all pairs with 0 or 5 
ng/ml TGF-β were visualized and photographed under same lighting conditions using 40x objective. 
Example positive cells were shown with red arrows, and example negative cells were shown with black 
arrows. 
 
  
 
 
53 
 
 
Figure 4.1.7 (continued): Global levels of H4K20me3 in HCC cell lines in the presence or absence 
of TGF-β induced senescence; determined by immunoperoxidase staining. 
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According to the results shown in Figure 4.1.7, H4K20me3 levels are low in poorly 
differentiated cell lines in comparison to the well differentiated cell lines. Most of the 
well differentiated cell lines, especially Hep3B and Hep40, also Hep3B-TR show a 
strong positive pattern. The difference between the staining patterns of the cell lines is 
more evident in Day 8 samples, and does not relate with TGF-β treatment. 
 
In order to confirm the results obtained from the immunoperoxidase staining 
experiments, western blotting technique was also employed. For the western blot 
analysis, a smaller panel of 9 cell lines was chosen which represented the strongly 
stained well-differentiated cell lines and the weakly stained poorly-differentiated cell 
lines. Histone extracts from these cell lines were separated in SDS-PAGE, and blotted 
with antibodies against H4K20me3 and unmodified H3, which served as an equal 
loading control. Results of this western blotting experiment is shown in Figure 4.1.8.  
 
Figure 4.1.8: H4K20me3 levels in HCC cell lines; determined by western blotting. Histone lysates 
from all cell lines were obtained by acid extraction as explained in the Materials and Methods section. 
4 μg of each lysate was loaded on a gel and blotted with H4K20me3 antibody. Unmodified H3 was 
used as a loading control. Ponceau S stained membrane is also shown in order to confirm equal 
loading. 
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Western blotting data confirmed the results obtained from immunoperoxidase 
staining. As seen in Figure 4.1.8, poorly differentiated cell lines, especially SNU-449, 
SNU-475 and FOCUS contained bands with weaker intensity when compared to well 
differentiated cell lines. 
 
4.1.1.8 Histone H4 lysine 20 monomethylation in HCC cell lines 
Immunoperoxidase and western blotting data for H4K20me3 levels let us to conclude 
that this histone mark was subject to a loss in poorly differentiated cell lines. 
H4K20me1 is the preferred substrate for the formation of trimethylated H4K20 mark, 
therefore, H4K20me3 levels are directly linked to H4K20me1 levels (Yang H, et al, 
2009). In order to gain information on which stage histone H4 lysine 20 starts to get 
affected in a manner that results in the loss of its methylation status, we wanted to 
analyze the monomethylation levels. Monomethylated histone H4 lysine 20 levels 
were also analyzed by western blotting, by using acid extracted histones similarly, as 
shown in Figure 4.1.9. 
 
Figure 4.1.9: H4K20me1 levels in HCC cell lines; determined by western blotting. 
Histone lysates from all cell lines were obtained by acid extraction as explained previously. 4 μg of 
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each lysate was loaded on a gel and blotted with H4K20me1 antibody. Unmodified H3 was used as a 
loading control. Ponceau S stained membrane is also shown in order to confirm equal loading. 
 
H4K20me1 western blotting revealed a similar pattern of H4K20 monomethylation 
with H4K20 trimethylation with the exception of SNU-449 cell line. These results 
raise the possibility that formation of the H4K20me1 mark might be affected in 
poorly differentiated cell lines which then results in the loss of H4K20me3. 
Nevertheless, they do not eliminate a possible change in the steps that lead from 
H4K20me1 to H4K20me3. 
 
4.2 Histone methyltransferases that act on H4K20 
There are three methyltransferase enzymes that are known to act on histone 4 lysine 
20. These three enzymes are: Set8, which functions as a monomethyl transferase, 
Suv4-20h1 and Suv4-20h2 which both function as dimethyl transferase and trimethyl 
transferases. In order to address a potential role, which is played by either one of these 
three methyltransferases, on the loss of H4K20me3 in poorly differentiated cell lines, 
we wanted to characterize the expression status of all the transcript variants of these 
three enzymes in our HCC cell line panel. Currently, there is no identified 
demethylase enzyme which is known to act on H4K20, therefore we had to 
concentrate on the methyltransferase enzymes and the specific roles they potentially 
play in the phenomenon.  
 
4.2.1 H4K20 methyltransferases Suv4-20h1 and Suv4-20h2 
Dimethyl and trimethyl forms of H4K20 are both catalyzed by Suv4-20h1 and Suv4-
20h2 enzymes which use the monomethylated form as the preferential substrate, and 
can also use the non-methylated form
 
(Yang H, et al, 2009). Gene information for 
these two enzymes were retrieved from Ensembl and NCBI databases, and RT-PCR 
primers for all different transcript variants were designed accordingly.  Exon 
structures, transcript variants and primer locations for these two genes are 
summarized in Figure 4.2.1. Suv4-20h1 gene has two isoforms. Variant 1, which is 
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the bigger isoform, codes for a 885 amino acid protein, with a predicted molecular 
weight of 99 kilo daltons. Variant 2, which is the smaller isoform, codes for a 393 
amino acid protein with a predicted molecular weight of 44 kilo daltons. Suv4-20h2 
gene has one canonical isoform according to Uniprot and NCBI databases, which is 
shown as Variant 1 in Figure 4.2.1.b, this isoform codes for a 462 amino acid protein 
with a predicted molecular weight of 52 kilo daltons. There is also one reported 
nonsense mediated decay product, according to Ensembl database, which is depicted 
here as Variant 2, and finally there is one other reported alternative splice product 
which is depicted here as Variant 3. 
 
Figure 4.2.1.a: Suv4-20h1 transcript variants and RT-PCR primers. Transcript variants 1 and 2 are 
depicted as Var1 and Var2. All exons are shown with rectangles. Filled rectangles represent translated 
regions, empty rectangles represent nontranslated regions. F1 is forward primer 1, R1 is reverse primer 
1, R2 is reverse primer 2. Variant 1 is analyzed by using F1 and R1 primers, Variant 2 is analyzed by 
using F1 and R2 primers. (Adapted from Ensembl genome browser) 
 
 
 
Figure 4.2.1.b: Suv4-20h2 transcript variants and RT-PCR primers. Transcript variants 1, 2 and 3 
are depicted as Var1, Var2 and Var3. All exons are shown with rectangles. Filled rectangles represent 
translated regions, empty rectangles represent nontranslated regions. F1 is forward primer 1, R1 is 
reverse primer 1, R2 is reverse primer 2. Variant 1 and Variant 2 are analyzed by using F1 and R2 
primers, and Variant 3 is analyzed by using F1 and R1 primers. Variant 1 is the canonical isoform. 
(Adapted from Ensembl genome browser) 
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4.2.1.1. Suv4-20h1 levels in HCC cell lines 
Total RNA was isolated from our 15 HCC cell lines, and cDNAs were synthesized 
from all. By using these cDNAs, Suv4-20h1 levels were analyzed via  RT-PCR with 
the primers shown in Figure 4.2.1.a. Variant 1 levels were addressed by using F1 and 
R1 primers, whereas Variant 2 levels were addressed by using F1 and R2 primers. In 
order to confirm the results obtained, RT-PCR experiments are repeated twice with 
two different RNA extracts. The results of these RT-PCR experiments are shown in 
Figure 4.2.2.  
 
 Figure 4.2.2: Suv4-20h1 levels in HCC cell lines, determined by RT-PCR. Transcript levels of 
Suv4-20h1 isoforms are determined by semi-quantitative RT-PCR. GAPDH (Glyceraldehyde-3-
phosphate dehydrogenase) is used as an internal control. (-) cntrl stands for negative control, without 
cDNA, to check for any nucleic acid contamination. 
 
According to the results shown in Figure 4.2.2, Suv4-20h1 Variant 1 is expressed in 
all HCC cell lines, with slight variations, for example transcript amount looks slightly 
more in SNU-387, and slightly less in SNU-449 when compared to GAPDH 
expression. Suv4-20h1 Variant 2 has more variations of expression between cell lines. 
Some of the poorly differentiated cell lines, such as SNU-423, SNU-449 and FOCUS 
have noticeably low levels of Variant 2. Differences seen between the two RNA sets 
might be due to differences in cell cycle profiles of the cells when pellets are 
collected. Since Suv4-20h1 levels are highly dependent on cell cycle stages, such 
slight variations are expected. Protein levels of Suv4-20h1 could not be examined in 
cell lines due to the lack of working antibodies. 
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4.2.1.2. Suv4-20h2 levels in HCC cell lines 
Total RNA was isolated from our 15 HCC cell lines, and cDNAs were synthesized 
from all. By using these cDNAs, Suv4-20h2 levels were analyzed similarly via  RT-
PCR with the primers shown in Figure 4.2.1.b. Variant 1 and Variant 2 levels were 
addressed by using F1 and R2 primers. PCR products of Variants 1 and 2 are 
differentiated according to product sizes, since Variant 1 PCR product is 553 base 
pairs, whereas Variant 2 PCR product is 387 base pairs. Variant 3 levels were 
addressed by using F1 and R1 primers. In order to confirm the results obtained, RT-
PCR experiments are repeated twice with two different RNA extracts. The results of 
these RT-PCR experiments are shown in Figure 4.2.3.  
 
Figure 4.2.3.a: Suv4-20h2 Variants 1 and 2 levels in HCC cell lines, determined by semi 
quantitative RT-PCR. GAPDH is used as an internal control. (-) cntrl stands for negative control. 
Upper band is Variant 1 (553 bp), lower band is Variant 2 (387 bp). 
 
Figure 4.2.3.b: Suv4-20h2 Variant 3 is not expressed in HCC cell lines, determined by semi 
quantitative RT-PCR. GAPDH is used as an internal control. (-) cntrl stands for negative control. 
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According to the results shown in Figure 4.2.3.a, Suv4-20h2 Variants 1 and 2 are 
expressed in all HCC cell lines, with slight variations. And according to Figure 
4.2.3.b, Suv4-20h2 Variant 3 is not expressed in HCC cell lines. Therefore, Suv4-
20h2 variants did not seem to be responsible for the loss of H4K20me3 mark in 
poorly differentiated cell lines. Protein levels of Suv4-20h2 again could not be 
analyzed due to the lack of a working antibody. 
 
4.2.2 H4K20 methyltransferase Set8 
Set8 is the only histone methyltransferase enzyme that is known to transfer one 
methyl group to unmodified histone H4 lysine 20 (Xiao B, et al, 2005; Coutre JF, et 
al, 2005). Since we were unable to identify a relationship between the loss of 
H4K20me3 mark in poorly differentiated cell lines and the status of the expression of 
Suv4-20h1 and Suv4-20h2 enzymes, the other candidate gene that might be involved 
in this process was Set8. Aberrations in Set8 expression could result in a loss of 
H4K20me1 levels, which in turn might result in a loss of H4K20me3 levels. The 
parallelism between H4K20me1 and H4K20me3 levels which were shown in Figures 
4.1.8 and 4.1.9 also supports this possibility. 
 
Information about Set8 gene was retrieved from NCBI and Ensembl databases, and 
RT-PCR primers were designed accordingly. Set8 gene has one canonical isoform 
according to NCBI database, which encodes for a protein of 352 amino acids, with a 
molecular weight of 39 kilo daltons. According to the Ensembl database, there are a 
total of 4 transcript variants, which are shown in Figure 4.2.4. Variant 1 is the 
mentioned canonical variant, and Variant 4 corresponds to the same protein product 
which only contains some difference in its nontranslated regions. Therefore variants 1 
and 4 are analyzed with the same primers: F1 and R2. Variant 2 is depicted as a 
nonsense mediated decay product in Ensembl, therefore it was eliminated from the 
analysis. Variant 3 had its first exon different from the canonical isoform, and 
encoded for a 229 amino acid protein with a molecular weight of 34 kilo daltons, and 
this variant was analyzed with primers F2 and R1. 
  
 
 
61 
 
Figure 4.2.4: Set transcript variants and RT-PCR primers. Transcript variants 1, 2, 3 and 4 are 
depicted as Var1, Var2, Var3 and Var4. All exons are shown with rectangles. Filled rectangles 
represent translated regions, empty rectangles represent nontranslated regions. F1 is forward primer 1, 
F2 is forward primer 2, R1 is reverse primer 1, R2 is reverse primer 2, R3 is reverse primer 3. Variant 1 
and Variant 4 are analyzed by using F1 and R2 primers, and Variant 3 is analyzed by using F2 and R1 
primers. F1 and R3 were designed to see the full length product. Variant 1 is the canonical isoform. 
(Adapted from Ensembl genome browser) 
 
4.2.2.1 Set8 Levels in HCC cell lines 
In order to analyze Set8 expression patterns in HCC cell lines, total RNA was 
extracted from all, and cDNAs were synthesized, as described in the Materials and 
Methods section. Set8 levels were analyzed using primers described in Figure 4.2.4 
by both semi quantitative RT-PCR and quantitative RT-PCR methods. RT-PCR 
experiments were repeated with 2 different sets of RNA in order to confirm the results 
obtained. The results of these experiments are shown in Figure 4.2.5. Additionally, in 
order to investigate the possibility that another alternative splice form might be 
expressed in HCC cell lines, F1 and R3 primers are used to set up a PCR reaction that 
resulted in the amplification of the full length product. For this purpose, three cell 
lines were chosen as representatives, and the results are shown in Figure 4.2.5.d. 
Since the three candidate cell lines only expressed the full length product of the 
expected size, this analysis was not extended to all cell lines. 
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Figure 4.2.5.a: Set8 transcript variants 1 and 4 levels in HCC cell lines, determined by semi-
quantitative RT-PCR. GAPDH is used as an internal control. (-) cntrl stands for negative control, to 
check for nucleic acid contamination in the PCR reaction. RT (-) stands for cDNAs that were 
synthesized without the addition of reverse transcriptase; therefore controls possible genomic DNA 
contamination. 
 
 
Figure 4.2.5.b: Set8 transcript variants 1 and 4 levels in HCC cell lines, by quantitative RT-PCR. 
F1 and R2 primers were used for Set8 amplification. Average of all cell lines was used as a reference, 
and fold changes were calculated with respect to that reference. Experiment was performed in 
triplicates, averages and standard deviations are shown. 
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Figure 4.2.5.c: Set Variant 3 is not expressed in HCC cell lines, determined by semi-quantitative 
RT-PCR. GAPDH is used as an internal control. (-) cntrl stands for negative control, to check for 
nucleic acid contamination in the PCR reaction. 
 
 
Figure 4.2.5.d: Expression of Set8 full length product in HCC cell lines, determined by RT-PCR. 
GAPDH is used as an internal control. (-) cntrl stands for negative control, to check for nucleic acid 
contamination in the PCR reaction. 
 
As can be interpreted from the results shown in Figure 4.2.5, only the canonical 
variant (Variants 1 and 4) of Set8 is expressed in HCC cell lines. Set8 expression 
levels vary greatly between cell lines; generally highly expressed in well 
differentiated cell lines, and low expressed in poorly differentiated cell lines. This 
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pattern of expression is consistent with the levels of H4K20me3 and H4K20me1 
levels in these cell lines. 
 
4.2.2.2 Set8 levels in patient liver tissue samples 
In order to gain an understanding of Set8 expression levels in human tissues, total 
RNA was isolated from 5 HCC-Cirrhosis paired patient tissue samples. cDNAs were 
synthesized from all, and Set8 canonical isoform  levels were determined by 
quantitative RT-PCR. According to the results of this experiment, which are shown in 
Figure 4.2.6, Set8 expression in human tissues is quite variable. In 4 out of 5 paired 
tissues, Set8 expression was reduced in HCC, which was expected. In the 5
th
 paired 
sample, it was the opposite.  
 
Figure 4.2.6: Set8 expression in patient liver tissue samples, determined by quantitative RT-PCR. 
F1 and R2 primers were used for Set8 amplification. Fold changes were calculated with respect to 
cirrhotic samples in each pair. Experiment was performed in triplicates, averages and standard 
deviations are shown. *: p-value < 0,01, **: p-value < 0,05, ***: p-value < 0,001 according to two-
tailed t-test. 
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4.2.2.3 Set8 Overexpression in SNU-475 cell line 
Since Set8 levels showed a noticeable correlation with HCC progression in both cell 
lines and patient tissue samples, we reasoned there could be a causative relationship 
between Set8 expression and HCC. Therefore we decided to employ overexpression 
strategy in order to search for a possible role of Set8 gene in HCC progression. SNU-
475 was the cell line with the lowest expression of Set8 in our cell line panel, so it 
was chosen to overexpress Set8 gene. Full length Set8 vector with HA-tag at the C 
terminal end was purchased from GeneCopoeia company (USA), and verified by 
sequencing, as shown in Figure 4.2.7. 
Alignment: 
CLUSTAL W (1.81) multiple sequence alignment (1 Mismatch) 
 
 
Set8-ENSEMBL-Var4                 MARGRKMSKPRAVEAAAAAAAVAATAPGPEMVERRGPGRPRTDGENVFTG 
Set8-NCBI                         MARGRKMSKPRAVEAAAAAAAVAATAPGPEMVERRGPGRPRTDGENVFTG 
T8950-Sequencing_Result_[Tra      MARGRKMSKPRAVEAAAAAAAVAATAPGPEMVERRGPGRPRTDGENVFTG 
                                  ************************************************** 
 
Set8-ENSEMBL-Var4                 QSKIYSYMSPNKCSGMRFPLQEENSVTHHEVKCQGKPLAGIYRKREEKRN 
Set8-NCBI                         QSKIYSYMSPNKCSGMRFPLQEENSVTHHEVKCQGKPLAGIYRKREEKRN 
T8950-Sequencing_Result_[Tra      QSKIYSYMSPNKCSGMRFPLQEENSVTHHEVKCQGKPLAGIYRKREEKRN 
                                  ************************************************** 
 
Set8-ENSEMBL-Var4                 AGNAVRSAMKSEEQKIKDARKGPLVPFPNQKSEAAEPPKTPPSSCDSTNA 
Set8-NCBI                         AGNAVRSAMKSEEQKIKDARKGPLVPFPNQKSEAAEPPKTPPSSCDSTNA 
T8950-Sequencing_Result_[Tra      AGNAVRSAMKSEEQKIKDARKGPLVPFPNQKSEAAEPPKTPPSSCDSTNA 
                                  ************************************************** 
 
Set8-ENSEMBL-Var4                 AIAKQALKKPIKGKQAPRKKAQGKTQQNRKLTDFYPVRRSSRKSKAELQS 
Set8-NCBI                         AIAKQALKKPIKGKQAPRKKAQGKTQQNRKLTDFYPVRRSSRKSKAELQS 
T8950-Sequencing_Result_[Tra      AIAKQALKKPIKGKQAPRKKAQGKTQQNRKLTDFYPVRRSSRKSKAELQS 
                                  ************************************************** 
 
Set8-ENSEMBL-Var4                 EERKRIDELIESGKEEGMKIDLIDGKGRGVIATKQFSRGDFVVEYHGDLI 
Set8-NCBI                         EERKRIDELIESGKEEGMKIDLIDGKGRGVIATKQFSRGDFVVEYHGDLI 
T8950-Sequencing_Result_[Tra      EERKRIDELIESGKEEGMKIDLIDGKGRGVIATKQFSRGDFVVEYHGDLI 
                                  ************************************************** 
 
Set8-ENSEMBL-Var4                 EITDAKKREALYAQDPSTGCYMYYFQYLSKTYCVDATRETNRLGRLINHS 
Set8-NCBI                         EITDAKKREALYAQDPSTGCYMYYFQYLSKTYCVDATRETNRLGRLINHS 
T8950-Sequencing_Result_[Tra      EITDAKKREALYAQDPSTGCYMYYFQYLSKTYCVDATRETNRLGRLINHS 
                                  ************************************************** 
 
Set8-ENSEMBL-Var4                 KCGNCQTKLHDIDGVPHLILIASRDIAAGEELLYDYGDRSKASIEAHPWL 
Set8-NCBI                         KCGNCQTKLHDIDGVPHLILIASRDIAAGEELLYDYGDRSKASIEAHPWL 
T8950-Sequencing_Result_[Tra      KCGNCQTKLHDIDGVRHLILIASRDIAAGEELLYDYGDRSKASIEAHPWL 
                                  *************** ********************************** 
 
Set8-ENSEMBL-Var4                 KH-------------- 
Set8-NCBI                         KH-------------- 
T8950-Sequencing_Result_[Tra      KHYASYPYDVPDYAGS 
                                  **  
 
 
P: Proline  R: Arginine HA-tag 
 
Figure 4.2.7: Clustal W multiple sequence alignment of the T8950-Set8 overexpression vector 
with the Set8 cDNA sequences from NCBI and Ensembl. There is one mismatch between the vector 
and the cDNA sequences from the databases, which is a reported SNP for this gene (NCBI SNP). 
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SNU-475 cell line was infected with Set8 vector via lentiviral infection method, as 
described in the Materials and Methods section. After two weeks of G418 selection, 
the obtained cell line was named as SNU-475-Set8. Success of the overexpression 
was confirmed by both Set8 RT-PCR, and HA-tag western blotting, as shown in 
Figure 4.2.8. After confirming that the overexpression was successful, H4K20me1 
levels were also compared between the parental cell line and over expression clone.  
H4K20me1 levels were determined by western blotting and a more sensitive method, 
flow cytometry. Results are shown in Figure 4.2.9. According to the results obtained 
by both methods, Set8 overexpression did not seem to affect H4K20me1 levels in 
SNU-475 cell line. 
 
 
Figure 4.2.8.a: Set8 mRNA levels in parental SNU-475 and Set8 overexpression clones, 
determined by quantitative RT-PCR. (1) and (2) are from two cell stocks of different freezing date. 
Fold changes are calculated with respect to parental SNU-475, averages and standard deviations of 
triplicates are shown. *: p-value < 0,01; **: p-value < 0,005 according to two tailed t-test. 
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Figure 4.2.8.b: HA-tag immunoblotting in parental SNU-475, SNU-475-Set8, and transiently 
transfected SNU-475 in whole cell lysates. SNU-475 cells were transiently transfected with Set8 vector 
to use as a positive control. Calnexin is used as an internal control. 
 
Figure 4.2.9.a: H4K20me1 levels were not affected by Set8 overexpression: western blot. Acid extracted 
histones were blotted with H4K20me1 and H3 antibodies. Unmodified H3 was used as an internal control.
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Figure 4.2.9.b: H4K20me1 levels were not affected by Set8 overexpression: flow cytometry. Rabbit IgG 
was used as isotype control.  
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4.2.2.4 Comparison of parental SNU-475 and SNU-475-Set8 overexpression clone 
SNU-475-Set8 cells were morphologically identical to SNU-475. In order to address the 
possible effects of Set8 overexpression on cellular growth rate, SNU-475 cell line was 
compared with parental SNU-475, first in terms of BrdU incorporation. Sub-confluent cells 
were seeded on coverslips and were labeled with thymidine analog 5-bromo-2-deoxyuridine 
(BrdU) for 2,5 hours. Cells were then fixed and stained by immunofluorescent staining with 
anti-BrdU antibody. BrdU positive cells were counted in five different chosen areas under the 
microscope, and the results are shown in Figure 4.2.10. Although SNU-475-Set8 showed a 
slightly lower BrdU positivity, the difference was not significant.  
 
 
Figure 4.2.10: There is no significant difference between SNU-475 and SNU-475-Set8 in terms of BrdU 
incorporation. Cells were labeled with BrdU for 2,5 hours, which was followed by immunofluorescent staining 
of BrdU positive cells. 5 different areas for each sample were counted, averages and standard deviations are 
shown.  
 
In order to measure the growth rates of the cells more sensitively, cellular growth rates were 
measured with Roche xCELLigence system, which allows to obtain real-time data about cell 
number, therefore is a powerful means to address growth rate. SNU-475 and SNU-475-Set8 
growth rates were compared with this system with different cell densities and different serum 
concentrations. The results are shown in Figure 4.2.11. 
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Figure 4.2.11: There is no significant difference between SNU-475 and SNU-475-Set8; determined by 
xCELLigence system.  Two separate experiments were performed in a) and b). In a), 1000 and 2000 cells / well 
were seeded in complete growth medium with 10 % FBS. According to these results, SNU-475-Set8 growth rate 
seems slightly lower. In b), 1000 cells / well were seeded with varying serum concentrations as indicated. 
According to these results, SNU-475 growth rates seems slightly lower, therefore we conclude that the observed 
differences are not important since they could not be reproduced. There is no observed effect of serum 
concentration on the difference between SNU-475 and SNU-475-Set8. 
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4.2.2.5 Set8 siRNA knockdown 
 As an alternative approach to investigate the potential roles that Set8 might play in HCC 
development, siRNA knockdown strategy was also employed. Two different Set8 siRNAs 
were used with a scrambled control, and siRNAs were transfected in HuH-7 cell line which 
was known to express high levels of Set8. The efficiency of Set8 siRNA knockdown  was 
confirmed by quantitative RT-PCR, and the results are shown in Figure 4.2.12. 
 
Figure 4.2.12: Set8 siRNA knockdown in HuH-7 cell line. HuH-7 cell line was transfected with the indicated 
siRNAs using Lipofectamine RNAi max reagent, as described in the materials and methods section. Total RNA 
was isolated and Set8 mRNA levels were determined by quantitative RT-PCR 24 and 48 hours post transfection. 
Fold changes are calculated with respect to non transfected, averages and standard deviations of triplicates are 
shown.  
 
Finally, all the data obtained from immunoperoxidase staining and western blotting  of 
histone methylation marks, and RT-PCR studies of H4K20 methyltransferase enzymes in 
HCC cell lines were summarized in Table 4.1.  
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CHAPTER 5. DISCUSSION 
 
In the first part of this study, we investigated the involvement of global levels of 
several histone modifications in HCC pathogenesis. As mentioned earlier, 
senescence, which is a characteristic of liver cirrhosis, acts as a barrier in front of 
tumorigenesis in the liver. The transition from cirrhosis to HCC is very important to 
understand the pathogenesis of HCC, which necessitates to understand the 
mechanisms involved in senescence bypass. Additionally, non cell autonomous 
senescence, which is induced by various stimuli is a promising phenomenon to be 
utilized in anti-cancer therapy (Senturk S, et al, 2010). In order to study the 
differences between immortal and senescent HCC cells, we used TGF-β induced 
senescence as a model in our cell line panel. 
 
It is an issue of debate whether the histone modifications in gene specific promoters 
are more important in biological processes, or global levels of certain histone 
modifications also carry information related to pathogenesis. In a recent study, global 
levels of H3K4me2, H3K18-ac and H3K9me2 were attributed prognostic 
significance in different cancer types (Seligson DB, et al, 2009). In our study, we 
investigated the involvement of several histone methylations, which are: H3K4me3, 
H3K9me3, H3K27me3, H3K36me3, H3R2me2, H3R17me2 and H4K20me3, in the 
development of HCC by using a cell line panel of 15 HCC cell lines, including well 
and poorly differentiated ones, in the case of senescence and immortality. The results 
we obtained however, did not reveal a prominent change in the global levels of any 
of these histone marks with respect to TGF-β induced senescence. This suggests 
global levels of the histone marks we studied are not affected by TGF-β induced 
senescence, although it is also a possibility that the difference might be beyond the 
sensitivity of immunoperoxidase staining method. 
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Histone 4 Lysine 20 trimethylation levels were observed to drop evidently in poorly 
differentiated HCC cell lines with respect to well differentiated cell lines, and this 
was consistently seen in both immunoperoxidase staining and western blotting 
experiments. This observation was in accordance with what was expected, since the 
loss of H4K20me3 is a common phenomenon in various cancer types, and since 
poorly differentiated cell lines represent advanced stages of HCC, and well 
differentiated cell lines represent earlier stages. Although not as obvious as trimethyl 
levels, monomethylated H4K20 levels also followed a similar pattern, as observed by 
western blotting. Therefore these data gave us a clue about the importance of H4K20 
methylation in HCC. 
 
Given that there are only three known methyltransferase enzymes which act on 
H4K20 residue, and there is no currently identified demethylase enzyme acting on 
this residue, we reasoned that one or more of the methyltransferases must be 
responsible for the global loss of H4K20me3 in poorly differentiated HCC cell lines. 
All different transcript variants of these genes were analyzed in our cell line panel by 
using specific primers for each. The initial analysis was performed by semi-
quantitative RT-PCR. Some of the analyzed variants were not expressed in HCC cell 
lines, therefore only the positive variants were evaluated. According to the RT-PCR 
data, none of the variants of Suv4-20h1 or Suv4-20h2 correlated with H4K20me3 
levels, which was quite surprising given that these are the enzymes that mediate the 
trimethylation of this residue. Nevertheless, the correlation between Set8 expression 
pattern and the H4K20 methylation pattern was impressive. After confirming this via 
quantitative PCR, we also analyzed Set8 expression levels in patient samples of 
HCC-cirrhotic paired tissues. We were unable to draw a conclusion about Set8 levels 
in normal tissues compared to the pathological samples, however in 4 of the 5 paired 
samples, HCC tissue showed lower levels of Set8 expression in comparison to the 
cirrhotic samples. This was also in support of what we had in vitro. Hence, we 
started to consider Set8 as a candidate to be responsible for the altered H4K20me3 
levels in HCC; in our model poorly differentiated cell lines.  
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In order to address a potential role for Set8 in HCC development, first we decided to 
employ overexpression strategy and analyze the newly obtained phenotype. For this 
purpose, we chose SNU-475 cell line to overexpress Set8 gene, since this was the 
cell line with the lowest expression values according to the quantitative PCR data. 
We obtained SNU-475-Set8 cell line via lentiviral infection of SNU-475 cell line 
with Set8 overexpression vector. The success of the overexpression was evaluated 
via several methods. Firstly, we used HA-tag immunoblotting, since our vector 
contained a C-terminal HA tag. The immunoblotting confirmed the expression of 
HA-tag, however that did not tell us much about neither the percentage of the cells 
that expressed the HA-tagged Set8, nor the extent of the overexpression. We tried 
confirmation with a Set8 specific antibody from Abcam, however the bands 
recognized by this antibody did not overlap with the HA-tag bands, and the 
recognized protein did not migrate as expected from Set8 protein (data not shown). 
Therefore we concluded the antibody recognized nonspecific bands, and we did not 
use that data. Next, we wanted to analyze the overexpression by immunofluorescent 
staining with the HA-tag antibody, however this was unsuccessful and we could not 
address HA-tagged Set8 levels by this method as well. The final strategy that we 
followed was evaluating H4K20me1 levels between the parental cell line and the 
overexpression clone. For this purpose, we used two techniques: western blotting and 
flow cytometry, and both revealed no changes between H4K20me1 levels. This 
might stem from multiple reasons. Firstly, the overexpression of Set8 might not be as 
effective to result in a change in H4K20me1 levels, since histones are very 
ubiquitous substrates and very high amount of protein might be required to make a 
recognizable change, although it should always be kept in mind that histones are not 
the only substrates of Set8 enzyme, and there can also be other proteins that Set8 can 
exert its effects on. Second, it might be beyond the sensitivity of the techniques we 
used to recognize the obtained change. Finally, it is also possible that there might be 
a compensatory mechanism in the cell that counteracts the newly introduced activity 
of overexpressed Set8 enzyme, such as the activity of an unidentified demethylase 
enzyme. 
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Even though the confirmation we could provide for the overexpression of Set8 in 
SNU-475 cell line was not completely robust, we assessed the changes associated 
with the overexpression of this protein. There were no initial morphological changes 
that we could observe following the overexpression. The first phenotypic effect we 
wanted to analyze was cellular growth rate. This was evaluated by BrdU 
incorporation, and much more sensitively with xCELLigence system. Neither of the 
methods revealed a significant difference between the tested cells. This suggests that 
Set8 overexpression does not have a role on the cellular growth rate of SNU-475 cell 
line, although it should also be kept in mind that this could be a misinterpretation 
because of the ineffectiveness of the overexpression. 
 
Alternatively, siRNA mediated knockdown was used as a new approach to the 
question in mind. HuH-7 cell line was chosen for the siRNA mediated knockdown 
due to its high expression of Set8, according to the qRT-PCR data. Although the 
knockdown was confirmed via qRT-PCR, confirmation at the protein level and the 
assessment of the effects of the knockdown remains to be worked on.  
 
Taken as a whole, according to the data obtained from this study, we were unable to 
identify a specific role of Set8 methyltransferase enzyme in the development of 
hepatocellular carcinoma. The intriguing question of whether the loss of H4K20me3 
histone mark in hepatocellular carcinoma has a causative relationship with the 
pathogenesis of HCC, or this is just a correlation, remains unanswered. It is also a 
possibility that the alterations in the methionine metabolism, rather than the 
methyltransferase enzymes might be responsible for the loss of H4K20me3 levels, 
and might be influential in the development of HCC. 
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CHAPTER 6. FUTURE PERSPECTIVES 
 
First of all, when working with global histone modifications, more sensitive methods 
such as flow cytometry or top down mass spectrometry could be used to obtain better 
results with higher precision. The screening study of global histone modifications in 
senescent and immortal cells could be repeated with such a technique. Also, gene 
promoter specific histone modification changes could be addressed by using specific 
candidate gene sets which are known to be involved in the mechanism of cellular 
senescence. Since our group has an already identified senescence – immortality gene 
set, that might be utilized in this respect. 
 
In order to further address the potential roles played by the Set8 gene, the siRNA 
knockdown study should be completed, first by proper confirmation of the 
knockdown in the protein level. The levels of H4K20me1 and H4K20me3 can still 
be unaffected from this knockdown, because the Suv4-20h enzymes can also use the 
monomethylated form as a substrate, and they might compensate for the loss of Set8. 
Nevertheless,  the big question regarding the issue of the histone code hypothesis 
also applies here: is it the particular histone modifications that are more important, or 
is it the enzymes that mediate these effects? Even though the siRNA knockdown 
ends up not affecting the histone modification levels, Set8 enzyme knockdown, even 
to a limited extent might reveal other important roles of Set8 enzyme, when it acts 
through other substrates. 
 
Additionally, Set8 stable over expression could be repeated to obtain more clones, 
and the most efficiently overexpressed clone can be selected. Therefore, a more 
powerful model will be obtained. Taken as a whole, Set8 enzyme is worth 
investigating more as a candidate gene to be involved in hepatocarcinogenesis. 
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